

Breast Cancer

CURRENT TRENDS IN MOLECULAR RESEARCH

Editors:

Shankar Suman

Shivam Priya

Akanksha Nigam

Bentham Books

Breast Cancer: Current Trends in Molecular Research

Edited By

Shankar Suman

*Comprehensive Cancer Center
The Ohio State University
Columbus
USA*

Shivam Priya

*Comprehensive Cancer Center
The Ohio State University
Columbus
USA*

&

Akanksha Nigam

*Department of Microbiology and Molecular Genetics
IMRIC, the Hebrew University- Hadassah Medical School
Jerusalem
Israel*

Breast Cancer: Current Trends in Molecular Research

Editors: Shankar Suman, Shivam Priya and Akanksha Nigam

ISBN (Online): 978-1-68108-952-2

ISBN (Print): 978-1-68108-953-9

ISBN (Paperback): 978-1-68108-954-6

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers - Sharjah, UAE. All Rights Reserved.

First published in 2022.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.net



CONTENTS

| | |
|---|-----|
| FOREWORD | i |
| PREFACE | ii |
| LIST OF CONTRIBUTORS | iii |
| CHAPTER 1 CELLULAR AND MOLECULAR MECHANISMS OF BREAST CANCER | |
| PROGRESSION | 1 |
| <i>Ajeet Kumar Verma, Sanjay Mishra, Puja Rani Mina and Swati Misri</i> | |
| INTRODUCTION | 1 |
| TYPES OF BREAST CANCER | 3 |
| Histological Subtypes | 3 |
| Non-invasive (or <i>in situ</i>) Breast Cancer | 4 |
| Invasive or Infiltrating Breast Cancer | 4 |
| Metastatic Breast Cancer | 4 |
| Molecular Subtypes | 4 |
| Luminal A | 5 |
| Luminal B | 5 |
| Triple-Negative/basal-like | 5 |
| HER2-enriched | 5 |
| Normal-like | 5 |
| CELLULAR AND MOLECULAR BASIS OF BREAST CANCER PROGRESSION | 6 |
| Molecular Mechanisms of Breast Cancer | 6 |
| Cellular Mechanisms of Breast Cancer Progression | 8 |
| Immune Cells and Breast Cancer Progression | 9 |
| Innate Immunity in Breast Cancer | 10 |
| <i>NK Cells</i> | 10 |
| <i>Myeloid-derived Suppressor Cells (MDSCs)</i> | 10 |
| <i>Macrophages</i> | 10 |
| Adaptive Immunity in Breast Cancer | 11 |
| <i>T Regulatory Cells (Tregs)</i> | 11 |
| B-lymphocytes | 12 |
| T-lymphocytes | 13 |
| SUMMARY AND FUTURE DIRECTIONS | 14 |
| CONSENT FOR PUBLICATION | 14 |
| CONFLICT OF INTEREST | 14 |
| ACKNOWLEDGEMENTS | 14 |
| REFERENCES | 14 |
| CHAPTER 2 IMMUNE-ENDOCRINE PERSPECTIVES OF BREAST CANCER | 22 |
| <i>Karan Singh Saini, Shankar Suman and Rituraj Konwar</i> | |
| INTRODUCTION | 23 |
| ORIGIN AND EVOLUTION OF BREAST CANCER | 24 |
| ANDROGEN RECEPTOR (AR) AND BREAST CANCER | 30 |
| Androgen Receptor in the Normal Breast | 30 |
| AR in Breast Cancer | 31 |
| AR as a Prognostic Factor for Breast Cancer | 31 |
| AR as a Therapeutic Target for Breast Cancer | 31 |
| CANCER CELLS AND IMMUNE RESPONSE | 32 |
| MECHANISM OF CANCER ESCAPE FROM IMMUNE SURVEILLANCE | 33 |
| ALTERING IMMUNOGENIC CHARACTERISTICS | 34 |

| | |
|---|----|
| SUPPRESSION OF IMMUNE RESPONSE BY IMMUNOSUPPRESSIVE FACTORS | 34 |
| Immunosuppressive Cells | 34 |
| Outpacing the Immune System | 35 |
| Cytokines in Breast Cancer | 35 |
| Cytokines and Steroids Synthesis | 37 |
| ANDROGENS AND THE IMMUNE SYSTEM | 38 |
| Androgens and Innate Immune System | 39 |
| <i>Neutrophils</i> | 39 |
| <i>Macrophages (Mϕ)</i> | 40 |
| <i>Dendritic Cells (Dcs)</i> | 40 |
| <i>Natural Killer Cells (NK Cells)</i> | 40 |
| ANDROGENS AND ADAPTIVE IMMUNITY | 41 |
| ANDROGENS AND CYTOKINES | 42 |
| CONCLUDING REMARKS | 43 |
| CONSENT FOR PUBLICATION | 43 |
| CONFLICT OF INTEREST | 43 |
| ACKNOWLEDGEMENTS | 43 |
| REFERENCES | 43 |
| CHAPTER 3 DNA DAMAGE RESPONSE: A THERAPEUTIC LANDSCAPE FOR BREAST | |
| CANCER TREATMENT | 62 |
| <i>Deepika Singh and Chandra Bhushan Prasad</i> | |
| INTRODUCTION | 63 |
| Risk Factors | 64 |
| SUBTYPES | 64 |
| Histological Classification | 64 |
| Molecular Classification | 66 |
| GENETIC PREDISPOSITION | 67 |
| GENOMIC INSTABILITY, DNA DAMAGE RESPONSE (DDR), AND CANCER | 68 |
| DNA AS A TARGET FOR CANCER THERAPY | 70 |
| Genomic Overview of Breast Cancer | 70 |
| Targeting DNA and DDR Response Associated Factors for Breast Cancer Therapy | 71 |
| NOVEL THERAPEUTIC STRATEGIES TARGETING DDR ASSOCIATED PATHWAYS | |
| FOR BREAST CANCER TREATMENT | 72 |
| PARP Inhibitors (PARPi) | 72 |
| DNA-PK Inhibitor (DNAPKi) | 73 |
| FEN1 Inhibitor | 74 |
| ATR/CHK1 Inhibitor | 74 |
| Wee1 Inhibitor | 75 |
| FUTURE DIRECTIONS | 75 |
| CONSENT FOR PUBLICATION | 75 |
| CONFLICT OF INTEREST | 76 |
| ACKNOWLEDGEMENTS | 76 |
| REFERENCES | 76 |
| CHAPTER 4 EMERGING TRENDS IN BIOINFORMATICS FOR BREAST CANCER | |
| MOLECULAR RESEARCH | 86 |
| <i>Sammed N. Mandape</i> | |
| INTRODUCTION | 86 |
| MULTI-OMICS DATA IN BREAST CANCER RESEARCH | 88 |
| Molecular Subtyping of Breast Cancer Using Multi-omics Data | 88 |
| PAN-CANCER STUDY USING MULTI-OMICS DATA | 90 |

| | |
|---|-----|
| BIOINFORMATICS METHODS IN BREAST CANCER RESEARCH | 92 |
| BIOINFORMATICS FOR UNDERSTANDING BREAST CANCER RESPONSE | 93 |
| BIOINFORMATICS TOOLS AND TECHNIQUES | 94 |
| CONCLUDING REMARKS | 100 |
| CONSENT FOR PUBLICATION | 101 |
| CONFLICT OF INTEREST | 101 |
| ACKNOWLEDGEMENTS | 101 |
| REFERENCES | 101 |
| CHAPTER 5 ROLE OF NITRIC OXIDE IN BREAST CANCER | 109 |
| <i>Ekhlaque A. Khan and Akhtar Parwez</i> | |
| INTRODUCTION | 109 |
| Physiological and Biological Action of Nitric Oxide | 111 |
| Various Roles of Nitric Oxide in Promoting Carcinogenesis | 112 |
| INVOLVEMENT OF NITRIC OXIDE IN VARIOUS TYPES OF CANCERS | 113 |
| Nitric Oxide in Cervix Uteri Cancer | 113 |
| HPV (Human Papillomavirus), Nitric Oxide, and Cervix Carcinoma | 114 |
| Nitric Oxide in Gastric Carcinoma | 114 |
| Nitric Oxide, H. pylori, and Gastric Carcinoma | 115 |
| Nitric Oxide in Head and Neck Carcinoma | 115 |
| Human Papillomavirus, Nitric Oxide, and Head Neck Carcinoma | 116 |
| Nitric Oxide and Lung Carcinoma | 116 |
| Nitric Oxide in Brain Tumor | 117 |
| Breast Cancer and Nitric Oxide | 117 |
| NITRIC OXIDE AND HORMONES INVOLVED IN BREAST CANCER | 117 |
| TUMORICIDAL <i>VERSUS</i> THE TUMOR-PROMOTING EFFECT OF NITRIC OXIDE | 118 |
| NITRIC OXIDE AS A BREAST CANCER THERAPEUTIC AGENT | 119 |
| CONCLUSIONS | 120 |
| CONSENT FOR PUBLICATION | 121 |
| CONFLICT OF INTEREST | 121 |
| ACKNOWLEDGEMENT | 121 |
| REFERENCES | 121 |
| CHAPTER 6 AUTOANTIBODIES AS CLINICAL BIOMARKERS IN BREAST CANCER | 129 |
| <i>Prachi Gupta</i> | |
| INTRODUCTION | 129 |
| Biomarkers | 129 |
| Breast Cancer Biomarkers | 130 |
| AUTOANTIBODIES | 130 |
| GOALS OF CANCER BIOMARKERS | 130 |
| AUTOANTIBODIES AS POTENTIAL CLINICAL MARKERS FOR CANCER | 131 |
| TECHNIQUES FOR AUTOANTIBODIES IDENTIFICATION | 132 |
| Recombinant cDNA Expression Cloning or SEREX | 132 |
| Serological Proteome Analysis or SERPA | 132 |
| Protein Microarray and Multiple Affinity Protein Profiling Or MAPPING | 132 |
| Protein Microarray | 133 |
| AUTOANTIBODIES TO INDIVIDUAL TUMOR ANTIGENS IN BREAST CANCER | 133 |
| AUTOANTIBODY PANELS FOR EARLY DETECTION OF BREAST CANCERS | 134 |
| CONCLUSIONS | 135 |
| CONSENT FOR PUBLICATION | 135 |
| CONFLICT OF INTEREST | 135 |
| ACKNOWLEDGEMENTS | 135 |

| | |
|---|-----|
| REFERENCES | 135 |
| CHAPTER 7 EPIGENETICS OF BREAST CANCER | 139 |
| <i>Manuraj Pandey, Archana Lalwani and Rajendra Mehta</i> | |
| INTRODUCTION | 139 |
| EPIGENETIC PROGRAMMING AND CELLULAR PHYSIOLOGY | 140 |
| Epigenetic Modifications are Strongly Interlinked | 141 |
| Epigenetic Imbalance in Cancer | 143 |
| BREAST CANCER AND EPIGENETICS | 143 |
| Methylome of Breast Cancer | 145 |
| <i>Histone Modification in BC</i> | 146 |
| EPIGENETICS IN CANCER PREVENTION AND THERAPY | 151 |
| EPIGENETICS AS A BIOMARKER OF CANCER | 151 |
| EPIGENETIC THERAPY IN CANCER | 153 |
| DNMT Inhibitors | 154 |
| <i>HDAC Inhibitors</i> | 155 |
| COMBINATION THERAPY | 155 |
| CONCLUDING REMARKS | 156 |
| CONSENT FOR PUBLICATION | 156 |
| CONFLICT OF INTEREST | 156 |
| ACKNOWLEDGMENTS | 156 |
| REFERENCES | 156 |
| CHAPTER 8 NANOPARTICLES TARGETING AND UPTAKE: CURRENT ADVANCES IN BREAST CANCER RESEARCH | 171 |
| <i>Onila Lugun and Alok Kumar Pandey</i> | |
| INTRODUCTION | 171 |
| INTERNALIZATION PATHWAYS | 172 |
| PHAGOCYTOSIS | 173 |
| PINOCYTOSIS | 174 |
| Clathrin-Mediated Endocytosis | 174 |
| Caveolae Mediated Endocytosis | 176 |
| Clathrin-Caveolae Independent Endocytosis | 176 |
| Macropinocytosis | 177 |
| RECEPTOR-MEDIATED INTERNALIZATION OF NANO-MEDICINE | 177 |
| Epidermal Growth Factor Receptor | 177 |
| CD44 Receptor | 179 |
| Folate Receptor (FR) | 179 |
| Formyl Peptide Receptor | 180 |
| LAT1 Transporter | 181 |
| Transferrin Receptor (TFR) | 181 |
| α/β Integrins | 183 |
| ESCAPING PHAGOCYtic CLEARANCE | 184 |
| CONCLUSIONS | 187 |
| CONSENT FOR PUBLICATION | 188 |
| CONFLICT OF INTEREST | 188 |
| ACKNOWLEDGEMENTS | 188 |
| REFERENCES | 188 |
| CHAPTER 9 DIETARY POLYPHENOLS AND ITS MOLECULAR MECHANISM IN THE MANAGEMENT OF BREAST CANCER | 196 |
| <i>Girish Rai, Sudhir Kumar Shekhar and Sarfraj Ahmad Siddiqui</i> | |

| | |
|---|-----|
| INTRODUCTION | 196 |
| Breast Cancer: An Overview | 198 |
| Molecular Subtypes of Breast Cancer | 199 |
| MOLECULAR MECHANISM OF ACTION OF POLYPHENOLS IN BREAST CANCER | 201 |
| Polyphenolic Compounds and Redox Balance | 201 |
| Polyphenolic Compounds and Uncontrolled Proliferation | 202 |
| Polyphenolic Compounds Regulating Apoptosis | 203 |
| Polyphenolic Compounds and Modulation of Inflammation-Related Factors | 204 |
| Polyphenolic Compounds and Modulation of the Estrogen Receptor | 205 |
| CONCLUSIONS | 206 |
| CONSENT FOR PUBLICATION | 206 |
| CONFLICT OF INTEREST | 207 |
| ACKNOWLEDGEMENT | 207 |
| REFERENCES | 207 |
| CHAPTER 10 RADIOTHERAPY IN CARCINOMA BREAST | 219 |
| <i>Teerthraj Verma, Mranalini Verma and Ratnasekhar Ch</i> | |
| INTRODUCTION | 219 |
| RADIOTHERAPY: DEFINITION AND PRINCIPLE | 220 |
| RADIATION SOURCES IN EXTERNAL BEAM RADIOTHERAPY | 221 |
| Telegamma (CO-60) Unit | 221 |
| MEDICAL LINEAR ACCELERATOR | 222 |
| Stand | 223 |
| Gantry | 224 |
| Head | 224 |
| Couch | 224 |
| Control Console | 224 |
| CARCINOMA BREAST | 225 |
| BREAST CANCER: TREATMENT MODALITIES OTHER THAN RADIOTHERAPY ... | 225 |
| EXTERNAL BEAM RADIOTHERAPY IN CA BREAST: DIAGNOSIS AND STAGING | 226 |
| STEPS IN EXTERNAL BEAM RADIOTHERAPY | 226 |
| SIMULATION | 227 |
| CT (VIRTUAL) SIMULATION: CLINICAL SETTINGS | 227 |
| TREATMENT PLANNING | 228 |
| CONTOURING WORKSTATION | 228 |
| Practical Aspects: Sites for Irradiation, Volume Concept | 229 |
| Postmastectomy Radiotherapy | 229 |
| Whole Breast Radiotherapy | 229 |
| Accelerated Partial Breast Irradiation | 229 |
| Regional Nodal Irradiation | 230 |
| TREATMENT PLANNING WORKSTATION: DOSE CALCULATION | 230 |
| CONCEPT OF DOSE FRACTIONATION | 231 |
| Conventional Radiotherapy | 231 |
| Hypofractionation | 231 |
| Hyper Fractionation | 231 |
| THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3DCRT) | 231 |
| DCRT With Uniform (Constant) Photon Fluence | 231 |
| INTENSITY MODULATED RADIOTHERAPY | 232 |
| DOSE AND FRACTIONATION OF RADIOTHERAPY | 233 |
| TREATMENT PLAN EVALUATION | 234 |
| VERIFICATION AND RADIATION DELIVERY | 235 |

| | |
|--|-----|
| BIOMARKERS (PROGNOSTIC AND PREDICTIVE) IN BREAST CANCER | |
| MANAGEMENT | 235 |
| CONCLUDING REMARKS | 236 |
| CONSENT FOR PUBLICATION | 236 |
| CONFLICT OF INTEREST | 236 |
| ACKNOWLEDGEMENT | 236 |
| REFERENCES | 237 |
| CHAPTER 11 AN OVERVIEW OF BREAST CANCER THERAPY | 242 |
| <i>Alkhansa S. Mahmoud, Zuki AB. Zakaria, Hazilawati HJ. Hamzah, Tengku Ahbrizal, F.T.A. and M.N. Mohd Hezme</i> | |
| INTRODUCTION | 242 |
| Neo-Adjuvant Therapy and Adjuvant Therapy | 243 |
| Surgery | 244 |
| Radiation Therapy | 244 |
| Chemotherapy | 246 |
| Hormone Therapy | 247 |
| Immunotherapy | 248 |
| SUMMARY AND CONCLUDING REMARKS | 251 |
| CONSENT FOR PUBLICATION | 251 |
| CONFLICT OF INTEREST | 252 |
| ACKNOWLEDGEMENT | 252 |
| REFERENCES | 252 |
| SUBJECT INDEX | 259 |

FOREWORD

Breast cancer malignancy is now becoming a global leading cause of cancer related death among females all around the world. The current developments in breast cancer research have wrought to increase the life expectancy in patients in the 21st century but a long way to go to cure this deadly disease. Among the major challenges, the heterogeneity in cancer cells make the disease more complex. Researchers have made a significant advancement in studying the heterogeneous features in breast cancer and multiple subsets of breast cancer are discovered. In the molecular biology studies, breast cancer stem-like cells, driver mutations and changes in tumor microenvironment are investigated as potentially hallmarks for the disease progression. Immunological aspects in breast cancer are considered cutting-edge science in recent discoveries. I am happy to look at this book that has incorporated all current advances in the breast cancer research. I congratulate Drs. Suman and Priya for editing a nice compilation of the different pieces of findings of breast cancer research in this book. I hope this will help to understand the recent advances in breast cancer to the researchers' particularly new investigators and clinicians.

Chandan Singh, PhD

Assistant Professor, Department of Biochemistry
Banaras Hindu University
India

PREFACE

Breast cancer is the most frequent malignancy in women worldwide. It is associated with several risk factors including mutations, inheritance, and environmental factors. The heterogeneity in breast cancer cells shows the complexity of this disease. Despite newer day-to-day developments in cancer research, advanced breast cancer is still challenging to manage. The scientific innovation in breast cancer research has led to an increase in patient's overall survival in the last few decades. For example- the discovery of sensitive screening tools enhanced early-stage detection of breast cancer and further novel treatment regimens improved therapeutic benefits. The current research is also focused on developing new surgical modalities that are minimally invasive, and new radiation modalities with minimal side effects. This book is intended to target a broad audience who has an interest in breast cancer research and therapy. We have incorporated chapters delineating the recent studies on breast cancer with an emphasis on etiology, diagnosis, and therapy. Chapters uncover the new updated information on breast cancer signaling, immune-response, DNA damage, and epigenetic modifications with bioinformatics resources. The book will allow readers to review the data of numerous studies on immunotherapy and gene therapy as well. The latest concept on the use of nanotechnology in breast cancer, has also been reviewed in detail as nanotechnology has opened a paradigm shift in targeted drug delivery in breast cancer. The specific chapter also shows the importance of dietary polyphenol and its role in breast cancer. The application of radiotherapy in breast cancer is also well described, which will be helpful to gain the concept of clinical radiotherapy. In overall, chapters are organized to give the readers a practical and efficient way to familiarize themselves with the newest ongoing research in the field of breast cancer.

Shankar Suman

Comprehensive Cancer Center
The Ohio State University
Columbus
USA

Shivam Priya

Comprehensive Cancer Center
The Ohio State University
Columbus
USA

&

Akanksha Nigam

Department of Microbiology and Molecular Genetics
IMRIC, the Hebrew University-Hadassah Medical School
Jerusalem
Israel

List of Contributors

| | |
|-------------------------------|---|
| Ajeet Kumar Verma | 840 Biomedical Research Tower, Wexner Medical Centre, The Ohio State University, Columbus Ohio, USA |
| Akhtar Parwez | Bhuwaneshwari Dayal College (B.D. College), Patna, India |
| Alkhansa S. Mahmoud | Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selango, Malaysia Radiobiology Department, Sudan Atomic Energy Commission, 1111 Khartoum, Sudan |
| Alok Kumar Pandey | Nanomaterial Toxicology Laboratory, Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31, Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India |
| Archana Lalwani | Department of Botany and biotechnology, Sadhu Vaswani Autonomous College, Sant Hirdaram Nagar, Bhopal, 462030, India |
| Chandra Bhushan Prasad | Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, India |
| Deepika Singh | Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, India |
| Ekhlaque A. Khan | Department of Biotechnology, Chaudhary Bansi Lal University, Bhiwani, Haryana, India |
| Girish Rai | Vivekanand Government PG College Maiha, MP, India Centre of Biomedical Research, SGPGIMS Campus, Lucknow, UP, India |
| Hazilawati H.J. Hamzah | Department of Veterinary Pathology and Microbiology, Faculty Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia |
| Karan Singh Saini | Govt. Kamla Nehru Girls College, Balaghat, M.P., India |
| M.N. Mohd Hezmee | Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selango, Malaysia |
| Manuraj Pandey | Department of Biotechnology, Unique College, Jawahar Chowk, T.T. Nagar, Bhopal, M.P., India |
| Mranalini Verma | Department of Radiotherapy, King George's Medical University, UP Lucknow, India |
| Onila Lugun | Nanomaterial Toxicology Laboratory, Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan, 31, Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India |
| Puja Rani Mina | Division of Gastroenterology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA |
| Prachi Gupta | Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA |
| Rajendra Mehta | Department of Rural Technology and Social Development, Guru Ghasidas Vishwavidyalaya (Central University), Bilaspur, CG, India |
| Ratnasekhar Ch | CSIR-Central Institute of Medicinal and Aromatic Plants Lucknow, Lucknow, India |

iv

| | |
|-------------------------------|--|
| Rituraj Konwar | CSIR- Central Drug Research Institute, Lucknow, India |
| Sammed N. Mandape | Center for Human Identification, University of North Texas Health Science Center, Fort Worth, Texas, USA |
| Sanjay Mishra | 840 Biomedical Research Tower, Wexner Medical Centre, The Ohio State University, Columbus Ohio, USA |
| Sarfraj Ahmad Siddiqui | Department of Zoolog, University of Lucknow, Lucknow, India |
| Shankar Suman | Biomedical Research Tower, Comprehensive Cancer Center, Ohio, USA |
| Swati Misri | 840 Biomedical Research Tower, Wexner Medical Centre, The Ohio State University, Columbus Ohio, USA |
| Teerthraj Verma | Department of Radiotherapy, King George's Medical University, UP Lucknow, India |
| Tengku Ahbriza F.T.A. | Malaysian Nuclear Agency, Ministry of Science, Technology and Innovation, Bangi, 43000 Kajang, Selangor |
| Zuki AB. Zakaria | Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selango, Malaysia |

CHAPTER 1

Cellular and Molecular Mechanisms of Breast Cancer Progression**Ajeet Kumar Verma^{1,*}, Sanjay Mishra¹, Puja Rani Mina² and Swati Misri¹**¹ 840 Biomedical Research Tower, Wexner Medical Centre, The Ohio State University, Columbus Ohio, USA² Division of Gastroenterology, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA

Abstract: Breast cancer is a common death-related cancer in women globally. Early and non-metastatic stage breast cancers are curable in 70-80% of the patients, while advanced-stage distant organ metastatic breast cancers are incurable with present treatment options. Although multiple risk factors are associated with breast cancer, among them, genetic predispositions in BRCA1 and BRCA2 genes are the most causative factor for breast cancer malignancy. The initiation and progression of breast cancer is a multi-step process, which can initiate either in ducts or lobules of the breast tissues. As time progresses pre-invasive lesions form of breast neoplasm transforms into atypical ductal hyperplasia (ADH), ductal carcinoma *in situ* (DCIS)/lobular carcinoma *in situ* (LCIS), and eventually become invasive carcinoma. The molecular mechanisms behind the initiation and progression of breast cancer are not completely understood. However, epithelial-mesenchymal transition (EMT) is the assurance of malignancy which disrupts endothelial integrity and therefore, it increases the spreading of cancer cells and facilitates metastasis. After the epithelial-mesenchymal transition of tumor cells, tumor cells invade and migrate the neighboring as well as distant tissues, cross the endothelial barrier and enter the blood, and attach to a secondary site, forming metastases. In this chapter, we have reviewed an overview of the molecular mechanisms of breast cancer progression.

Keywords: EMT, Hyperplasia, Malignancy, Treg, Tumor cells.

INTRODUCTION

Breast cancer is the most common carcinoma and has a high incidence rate amongst all types of women cancer worldwide [1]. Breast cancer is a heterogeneous disease, which can be divided into several subtypes based on histological appearance and the expression of molecular markers.

* Corresponding author Ajeet Kumar Verma: 840 Biomedical Research Tower, 460 West 12th Avenue, Columbus, Ohio, USA-43210; E-mail: ajeetsonicdri@gmail.com

In the United States, it is approximated that one in eight women will develop breast cancer in her lifetime. This development of breast cancer is a complex process, which is multistep events from initiation, progression, to metastasis. The mechanistic basis of breast cancer metastasis is the epithelial to mesenchymal transition (EMT) [2].

Cancer cell migratory nature is defined by EMT and its converse MET (mesenchymal-epithelial transition) process. There are a series of events that happen when cells transform from epithelial to mesenchymal stages, like cell junction loss and acquiring the migrant nature. During the transformation process, the cells lose their “epithelial” characteristics such as cell to cell adhesion, cell junctions, and cells that express vimentin as the key intermediate filament protein. Undoubtedly, EMT is a shorthand that means changes in the cell shape from coherent “epithelial” monolayer to a migratory fibroblastic or “mesenchymal” phenotype.

The discovery of more driver genes and the complex molecular pathways of breast cancer pave a better understanding of disease progression. Based on the expression profiles of various genes, breast cancer has been categorized into five distinct subtypes: luminal A, luminal B, normal-like, basal-like, and human epithelial growth factor receptor 2 (HER2) types. All these subtypes have different clinical consequences and therapeutic options [3]. The oncogenes strongly influence the changes in malignancy and distant metastasis. Normal breast stromal cells transform into cancer cells by gain-in-function mutations (oncogene). These mutant genes are driver oncogenes that dysregulate apoptotic pathways to become resistance phenotypes. Further constant oncogenic pressure dilutes the effect of existing chemotherapies and thereby leads to poor patient survival. Thus, targeting oncogenic drivers and their downstream signaling molecules are being pursued rationally for breast cancer. For example, luminal or HER2-positive subtypes of breast cancers are getting treated with endocrine therapies or HER2 targeted therapies. In addition, molecular mechanism-based therapies have brought a paradigm shift in recent therapy. Such therapies consist of DNA repair PARP protein inhibitors for BRCA-mutant basal cancer subtype or CDK4/6 inhibitors for advanced ER+ HER2- breast cancers. Several clinical trials are uncovering the potential therapeutic use of immune checkpoint inhibitors as monotherapy or with other target-based therapies for breast cancer. Additionally, the role of different immune cells and molecular markers in the development and metastasis of breast cancer has been explored in past decades which led to the development and use of immunotherapy for breast cancer patients.

The family history of having breast cancer or if any close relatives, such as a mother, sister, or daughter ever been diagnosed with breast cancer, the probability

of having breast cancer rises at an early stage *i.e.*, premenopausal age [4 - 6]. Despite the advancements in treatment, the five-year survival risks for patients with metastatic breast cancer are still only very low (22%) [7], and breast cancer still directly affects one in every eight U.S. women [8]. Breast cancers can be sub-categorized based on the expression of distinct molecular and histological markers. Infiltrating ductal carcinoma (~85%) and infiltrating lobular carcinoma (~15%) are categorized as the main histological subtypes of invasive breast cancer [6]. Approximately 75% of all Breast cancer patients have molecular signatures that are designated as hormone receptor-positive cancers, expressing either estrogen receptor (ER) or progesterone receptor (PR) at higher than 1%. Because of the receptor's overexpression, these cancers can be targeted by drugs that directly target the receptors like tamoxifen or aromatase inhibitors. Another group of treatable breast cancers includes human epidermal growth factor receptor 2 (HER2) positive (15-20%), which tend to grow faster than HER2 negative breast cancers, but it can be targeted with anti-Her2 therapies such as trastuzumab [6]. While there has been a success in finding drugs that treat and cure early-stage, ER, PR, and HER2 positive breast cancers, there are no approved target-based therapies to date for triple-negative breast cancer (TNBC). The TNBC patients (~15%) do not display high amounts of any of these molecular markers [6]. For this reason, patients with TNBC have a higher likelihood of recurrence and lower five-year survival rates than those diagnosed with other subtypes of breast cancer.

TYPES OF BREAST CANCER

Breast cancers are classified based on their presence in different areas of the breast such as lobules, ducts, or within tissues. However, based on cell origin, breast cancers are broadly categorized as carcinomas and sarcomas. Carcinomas are the type of breast cancer that arises from epithelial components lying between lobules and terminal ducts. Sarcomas are a very rare form of breast cancer (it is less than 1% of total breast cancer) that arises from the stromal constituents of the breast, these include myofibroblasts and blood vessel cells. These categorizations are inadequate because sometimes a single mammary tumor can be a mixture of different cell types [9 - 11]. Breast cancers generally fall into two subtypes, histological subtypes, and molecular subtypes.

Histological Subtypes

Most breast cancers are diagnosed with carcinoma. Under carcinomas, many different types of breast cancer are recognized based on invasiveness compared to the primary tumor sites. Breast cancers fall under three major groups based on pathological characteristics and invasive properties which are non-invasive (or *in situ*), invasive, and metastatic breast cancer types [9 - 11].

Immune-Endocrine Perspectives of Breast Cancer

Karan Singh Saini^{1*}, Shankar Suman² and Rituraj Konwar³

¹ Govt. Kamla Nehru Girls College, Balaghat, M.P. India

² The Ohio State University, Columbus, Ohio, USA

³ CSIR- Central Drug Research Institute, Lucknow, India

Abstract: Cancer is the consequence of the recalcitrant multiplication of the transformed cells. Cancer cells grow and proliferate at a fast pace and do not follow normal regulation of cell division. Breast cancer is a heterogeneous group of diseases, which is the second leading cause of death among women. Although androgen is primarily considered a male steroid hormone, it also has an important role in the female reproductive system. The literature evidence suggests the role of androgen receptors (AR) in the normal development of the breast. At puberty, the expression of AR is even more than ER, suggesting its importance during the process of sexual development; its activity maintains the ER-induced cell proliferation and normal development of the breast. Epidemiological studies have suggested a positive correlation between high endogenous androgens and the risk of breast cancer in both pre- and postmenopausal women. In both ER and PR-positive breast cancers, AR is expressed in 60-70% of the cases. AR is also reported to be co-expressed with ER in around 80-90% of breast cancer cases and is considered an independent prognostic factor of ER-positive breast cancers. Tumor-microenvironment has a complex role in tumor initiation, progression, and metastasis. Tumor-infiltrating and resident cells secrete a variety of inflammatory and anti-inflammatory cytokines, which in turn either inhibit or promote tumor growth. Immunosuppressive and immuno-inductive effects of androgen have been reported in various studies. Androgens have been reported to influence the adaptive immune system more than the innate immune system in many ways. Crosstalk of androgen and cytokine signaling has many effects in breast cancer epidemiology. So, in this chapter, we will discuss the various immune-endocrine perspectives of breast cancers.

Keywords: Adaptive immunity, Androgens, Apocrine breast cancer, Cancer immunoediting, Dihydrotestosterone, Innate immunity, T cytotoxic cells, T helper cells.

* Corresponding author Karan Singh Saini: Govt. Kamla Nehru Girls College, Balaghat, M.P., India; E-mail: karanbt14@gmail.com

INTRODUCTION

Cancer is the consequence of the recalcitrant multiplication of the transformed cells of a particular tissue or organ of the body.

Cancer cells grow and proliferate in an uncontrolled manner and do not follow normal constraints on division and are able to invade and colonize the surrounding tissues *via* the process of metastasis. Normal cells abide by specific pro- and anti-signals for processes like proliferation, growth, and differentiation. Development of cancer requires promoting assaults like mutagenesis [1], inflammation [2], and gradual accumulation of genetic [3] and epigenetic changes [4]. Cancer cells develop self-sufficiency for proliferation and promoting signals and become insensitive to growth and proliferation inhibiting signals [5]. When normal cells face irreparable DNA damage, they stop dividing and undergo programmed cell death (apoptosis), while cancer cells become resistant to apoptosis [6]. Cancer cells also bypass the limits of replication potential through elevated telomerase enzymes and alternative telomere lengthening (ALT) and can replicate limitlessly even with errors in DNA [7, 8]. At each step of progression, cancer cells acquire additional changes to counteract new challenges like limited nutritional supply through processes of altered energy metabolism [9], angiogenesis [10], migration, and metastasis to more favorable locations [11]. Cancer is like an overall self-destructive program created by selecting robust abnormal cells in the body and can only be tamed to a large extent by therapeutic interventions.

Breast cancer is predominantly carcinoma of the cells of breast tissue arising as a result of uncontrolled cell division of epithelial cells of mammary ducts or acinar cells forming lobules of the breast. The breast is a dynamic organ in the sense that its growth is greatly influenced by reproductive hormones and can proliferate and differentiate for fulfilling the requirement of generating milk for a particular post-pregnancy window of reproductive life. The breast is a modified sweat gland composed primarily of fibrous and adipose tissues along with glandular epithelial tissue organized in the form of ducts and lobules. The basic unit of the mammary gland is acini that are lined by milk-secreting simple cuboidal cells surrounded by a layer of myoepithelial cells. Acini joined to form lobules that open into intralobular ducts, which will, in turn, empty into larger interlobular ducts finally into 15-20 lactiferous ducts to drain the milk through the nipple. Protective connective tissues surround lobules and ducts in the form of intra-lobular connective tissue and interlobular connective tissues giving support to glandular components of the breast.

Breast cancer is the second most common malignancy among women, accounting for 25% of the types of cancers [12]. In 2012 approximately 1.7 million new cases of breast cancer (11.9%) were reported and ranked as the fifth cause of death among cancer deaths (deaths, 6.4%). Affecting women in less developed regions (deaths, 14.3% of total), while the second cause of cancer death in more developed regions (deaths, 15.4%) [13]. One woman out of eight is at the risk of getting breast cancer [14]. According to the NCRP, 2012 report issued by ICMR, the estimated number of breast cancer cases in India was 144,937 (27%) in 2012 and ranked second after cervical cancer.

ORIGIN AND EVOLUTION OF BREAST CANCER

The initiation of breast cancer is the result of the accumulation of genetic and epigenetic changes and subsequent tumor progression is driven by clonal expansion and selection of mutated cells [15]. Accumulation of genetic mutations can lead to the change in internal signaling and normal cellular control in the breast. The continual replication of corrupted cells results in the formation of a colony of abnormal cells termed '*In situ* hyperplasia' which further leads to invasive carcinomas, and finally the metastatic form of the disease [16, 17]. Epithelial-mesenchymal interactions play a key role in the normal development of the mammary gland as well as for breast tumorigenesis [18]. *In vivo* and *in vitro* studies have demonstrated that the tumor microenvironment is composed of myoepithelial, endothelial cells, fibroblasts, myofibroblasts, leukocytes, and other cell types. The extracellular matrix (ECM) molecules regulate the tissue specificity of the normal breast as well as the growth, survival, polarity, and invasive behavior of breast cancer cells [19, 20]. Cytokines secreted by the resident or infiltrating cells of the tumor microenvironment could have a supporting or inhibiting role in the tumor growth and progression.

Sex steroid hormones play an important role in the development and physiological function of the mammary gland. Estrogens induce the proliferation of duct epithelial cells, blood vessel growth, and connective tissue while progesterone is responsible for tubulo-alveolar cell differentiation and development [21 - 24]. Androgens have been reported to suppress the proliferation of mammary epithelial cells [25 - 27]. Therefore, corresponding steroid receptors like estrogen receptor (ER) and androgen receptor (AR) can be strongly associated with the risk of initiation and progression of breast cancer. Recent reports suggest that AR is most predominantly (70-90%) expressed steroid receptors in a few subtypes of breast cancer [28 - 33]. The high level of estrogen among women is significantly associated with the risk of breast cancer [34 - 37]. Similarly, the level of androgen in postmenopausal women is associated with the risk of breast cancer [34, 38].

DNA Damage Response: A Therapeutic Landscape For Breast Cancer Treatment

Deepika Singh¹ and Chandra Bhushan Prasad^{1,*}

¹ Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, India

Abstract: Breast cancer is responsible for cancer-related death among women globally. The known causes of breast cancer include genetic predisposition, dysregulated hormonal signaling due to psychological stress, and aging and lifestyle factors, such as smoking and alcohol consumption. Due to improved treatment strategies, the overall survival is significantly increased; however, it is still significantly associated with death worldwide. Breast cancer's initiation and progression are strongly influenced by genomic instability. Defect in DNA damage response (DDR) pathways, which enable cells to survive, help in the accumulation of mutation, clonal selection, and expansion of cancer cells. Germline mutation in breast cancer susceptibility genes, BRCA1 and BRCA2, TP53, and PTEN, increases the risk of early onset of disease. During the initial and clonal selection of cancer cells, a defect in one DNA repair pathway could potentially be compensated by another pathway. Therefore, cancer cells with defective DNA repair pathways could be easily killed by targeting the compensatory pathways by inducing synthetic lethality. Evidently, cancer cells with defective DDR or decreased DNA repair capacity show synthetic lethality in monotherapy when the backup DNA repair pathway is inhibited. For instance, tumors with defective homologous recombination (HR) can be targeted by inhibitors of double-strand break repair enzymes. Here, we briefly addressed the relevant factors associated with the development of breast cancer and the role of the DDR factor in the development of breast cancer. In addition, recent treatment strategies targeting genomic instability in breast cancer will be summarized as well as how the genomic instability and defective DDR can be targeted for the treatment of breast cancer.

Keywords: DNA damage, DNA damage response, DNA repair, PARP inhibitor, Synthetic lethality.

* Corresponding author Chandra Bhushan Prasad: Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, India-221005; Tel: +91-542-6702496; E-mail: Chandrabhushan.onco@gmail.com

INTRODUCTION

Breast cancer is a common cause of death associated with malignancy in women around the world.

In 2018, nearly 2.09 million cases of breast cancer in women were newly diagnosed and an estimated death occurred was 626,679 [1]. The graph of global incidence has been rising in breast cancer with an annual increase of 3.1%, beginning with 641,000 cases in 1980 and rising to more than 1.6 million in 2010 [2]; this trend still continues. Furthermore, the epidemiology of breast cancer requires more research as many countries register diagnoses and deaths but no relapses. One study reported that in 2017, the United States alone had approximately 160,000 cases of advanced-stage breast cancer [3].

The frequency of breast cancer incidence varies worldwide. The incidence rate is higher in high-income regions vis-à-vis low-income regions. The highest incidence rate is observed in high-income countries (HIC) such as New Zealand, North America, Australia, and northern and western Europe [4]. However, only 53% of all cases occur in less developed countries. In contrast to the increase in incidence, the mortality rate decreases in HICs, as cancer is usually diagnosed at an early stage, and with the availability of mammography, the prognosis is in the right direction. However, in low and middle-income countries the diagnosis is mainly as a late-stage often leading to poor survival. The mortality rate due to breast cancer is among the highest in many low and middle-income countries like the Caribbean islands (Bahamas), Pacific Islands (Fiji), Africa (Nigeria), sub-Saharan, and southern Asia (Pakistan) [5], despite their lower incidence. This is probably due to the late onset of the disease, and limited access to early detection and treatment.

Studies show that the median age of women when she is diagnosed is nearly 61 years with a peak range between 60 to 70 years in western countries; however, in Asian countries, the disease presentation is earlier, and the peak range is between 40 to 50 years [2]. In addition, the patients detected with breast cancer are almost 10 years younger in developing countries as compared to developed countries [6]. The biology of tumors also varies with ethnicity eg., African and African-American women are highly diagnosed with triple-negative breast cancer (TNBC) as compared to any other ethnic group [7]. They also represent increased cases of metastatic disease and the majority of poorly differentiated and undifferentiated grades among all subtypes, all of these conditions lead to lower survival. Moreover, 9% of breast cancers diagnosed in non-Hispanic black women are metastases which, in other ethnic groups, represent between 5% and 6% [8].

In men, breast cancer is a rare disease, accounting for nearly 1% of all breast cancers. According to the American cancer society, the risk of getting diagnosed breast cancer in men is 1 in 833. The risk is greater in black men as compared to non-Hispanic white men [9].

Risk Factors

Major risk factors include age, family history, alcohol consumption, reproductive factors (including nulliparity, early age at menarche, later menopause, and first childbirth after 30 years of age), physical inactivity, use of menopausal hormone therapy, and use of contraceptive pills [10, 11]. Obesity and being overweight are also linked with post-menopausal breast cancer. However, there is no such evidence that shows the effect of these factors on premenopausal breast cancer [12]. Furthermore, breastfeeding reduces the risk of having breast cancer [13]. A continuous event of lesions and accumulation of genetic modifications at the morphological level promotes a normal gland to cancer (Fig. 1).




Fig. (1). Breast cancers originate in the epithelial cells of terminal ductal lobular units of collecting ducts.

SUBTYPES

The methods to classify breast cancer in different biological subtypes include molecular pathology, histopathology, genetic analysis, and gene expression profiling.

Histological Classification

Breast cancer can be broadly divided into *in-situ* carcinoma and invasive (infiltrating) carcinoma. Based on the pattern of growth and cytological characteristic features, breast *in situ* carcinoma is further categorized into lobular or ductal. Ductal carcinoma *in situ* (DCIS) is more common than lobular carcinoma *in situ* (LCIS) and comprises a heterogeneous group of tumors. DCIS

Emerging Trends in Bioinformatics for Breast Cancer Molecular Research

Sammed N. Mandape^{1,*}

¹ Center for Human Identification, University of North Texas Health Science Center, Fort Worth, Texas, USA

Abstract: Applications of bioinformatic methods and high-throughput sequencing techniques have increased exponentially over the last decade, transforming the way we understand complex malignancies such as breast cancer. In this chapter, an overview of recent advances in molecular research in breast cancer using emerging bioinformatics methods is presented. Learnings from scientific studies that have successfully integrated and interpreted massive amounts of data generated from various platforms (multi-omics data) using bioinformatics approaches are also outlined. Additionally, pan-cancer studies that help identify the differences and commonalities across multiple cancers are reviewed. We also discuss bioinformatics applications that transform the way we decipher the OncoGenomic landscape of breast cancer. Finally, this study also summarizes current publicly available bioinformatics tools and databases for breast cancer research.

Keywords: Bioinformatics, Genomics, High-throughput sequencing, Multi-omics, Next-generation sequencing, Pan-cancer analysis, Transcriptomics.

INTRODUCTION

In recent years, the advances in technology to generate and analyze large amounts of biological data have helped improve the clinical treatment and management of breast cancer [1]. However, the incidence rate remains a concern. For the past few years, breast cancer has been one of the most common cancers diagnosed among women globally, accounting for about 25% of cases worldwide [2]. In 2021, it was estimated that the USA alone would report around 280,000 new breast cancer cases in women [3 - 5]. According to ACS (American Cancer Society), the breast cancer mortality rate has decreased 40% from 1989 through 2017 compared to a 0.4% yearly rise until 1989 [3 - 5]. Although the 5-year survival rate currently stands at 90% for women with invasive breast cancer, 20-30% of patients are

* **Corresponding author Sammed N. Mandape:** Center for Human Identification, University of North Texas Health Science Center, Fort Worth, Texas, USA; E-mail: sammed.mandape@unthsc.edu

reported to display metastatic relapse over time [3 - 5]. The prognostic outcome of patients who initially present with breast cancer is dependent on many factors such as early detection, tumor stage at detection, breast cancer subtype, and biological characteristics of the tumor [3 - 5]. Moreover, breast cancer subtypes like triple- negative breast cancer (TNBC) have a high metastasis rate and shorter survival time. Recurrence of tumor after the initial clinical intervention, chemoresistance, and evolving genomic changes in cancer cells also pose severe challenges for the effective treatment of breast cancer [3 - 5]. The developments in sequencing technologies, specifically massively parallel sequencing and microarray technologies, have profoundly changed our understanding of breast cancer dynamics and led to significant breast cancer research advancements [6, 7]. Additionally, not only is data readily generated and analyzed, but it is now efficiently stored and shared between research groups. The rise in cloud technology presents the scientific community with an unprecedented opportunity to access large amounts of publicly available breast cancer data for an in-depth understanding of tumor cell biology [8]. Over the last decade, high-throughput sequencing data analysis using bioinformatics methods has led to promising molecular discoveries in the realm of breast cancer research (Table 1).

Table 1. Key discoveries in the past decade.

| Year | Key Discovery |
|------|---|
| 2011 | A large meta-analysis of more than 10,000 breast cancer female patients found that radiotherapy delivered after breast-conserving surgery significantly reduces the risk of recurrence and breast cancer mortality [9]. |
| 2012 | An integrative breast cancer data analysis identified four main breast cancer classes based on genetic and epigenetic modifications. Multi-omics data found somatic mutations in three genes, TP53, PIK3CA, and GATA3 showed the highest incidence (>10%) in all breast cancers. Basal-like breast tumors were shown to share many molecular commonalities with serous ovarian cancer [10]. |
| | A multi-omics approach combining the power of whole-exome DNA sequencing and whole-genome sequencing, Banerji et al., identified six genes (<i>CBFB</i> , <i>TP53</i> , <i>PIK3CA</i> , <i>AKT1</i> , <i>GATA3</i> , and <i>MAP3K1</i>) significantly mutated in breast cancer. The study, further, established the frequent involvement of AKT3 in recurrent genomic fusion events. These findings opened the door to investigating the role of AKT3 inhibitors for treating fusion-positive breast cancer subtypes like TNBC [7]. |
| 2015 | Almost all cases of invasive lobular carcinoma (ILC), the second most prevalent histological subtype of invasive breast cancer, showed loss of CDH1 at DNA, mRNA, and protein levels. The Cancer Genome Atlas (TCGA) multi-omics study, also, identified significant mutations in PTEN, TBX3, and FOXA1, shedding light on the genetic signatures of ILC [11]. |
| 2016 | National Cancer Institute (NCI) launched the largest-ever breast cancer study to investigate the inherited genetic variations associated with breast cancer in 20,000 black women. This study investigates the gene expression and genetic pathways involved in breast cancer [12]. |

(Table 1) cont....

| | |
|------|--|
| 2017 | Ogivri, the first biosimilar drug, was approved by the US Food and Drug Administration (FDA) for breast cancer treatment [13,14]. |
| | A case series study using high-throughput sequencing data of metastatic breast cancer provided critical molecular insights into treatment-resistant metastatic breast cancer. Single-cell RNA sequencing was used to identify phenotypic characteristics of individual cancer subclones from the metastatic breast cancer samples [15] |
| 2018 | Landmark TAILORx study reported that 70 percent of women with early-stage breast cancer receive no benefit from chemotherapy and can be treated with endocrine therapy alone [16,17]. |
| | TCGA published the Pan-Cancer Atlas, a comprehensive collection of research articles based on cross-cancer analyses using the TCGA cancer data to understand the oncogenic processes, pathways, and cell of origin patterns across multiple cancers [18]. |
| 2019 | Hormone receptor-positive metastatic breast cancer showed complete regression after treatment with tumor-infiltrating lymphocytes reactive against specific mutant proteins [19]. |
| 2020 | Researchers identified infiltration of tumor microenvironment with certain types of immune cells as one of the molecular changes that potentially can explain the exceptional response to treatment [20]. |

MULTI-OMICS DATA IN BREAST CANCER RESEARCH

Omic data facilitate an interface to study molecular dynamics of tumor cells from multiple levels - genomic, epigenomic, proteomic, transcriptomic, and metabolomic. Such high-dimensional data can provide a more accurate view of the driving mechanisms of a heterogeneous disease like breast cancer.

One of the major public repositories of multi-omics data very often used is The Cancer Genome Atlas (TCGA) which has over 20,000 samples (primary cancer and matched normal) that span 33 cancer types [21]. Breast cancer samples in TCGA have been classified, based on genetic features, into two invasive types; more common invasive ductal carcinoma (65-85% of all breast cancer) and invasive lobular carcinoma (ILC) (about 10% of all breast cancer) [10, 11, 22]. Other commonly used publicly available multi-omics data repositories include national center for biotechnology information's (NCBI's), gene expression omnibus (GEO) [23] and European bioinformatics institute's (EBI), BioStudies database (previous platform was ArrayExpress) [24]. All these sources allow the research community to access data generated experimentally from studies carried out worldwide. The data in these sources include microarray, metabolomic, proteomic, transcriptomic, genomic, and other biological data generated by high-throughput technologies [25, 26].

Molecular Subtyping of Breast Cancer Using Multi-omics Data

Breast cancer is a heterogeneous disease encompassing multiple molecular subtypes that present varied genomic profiles, clinical characteristics, histopathological features, and prognostic outcomes [27]. Gene expression studies

Role of Nitric Oxide in Breast Cancer

Ekhlaque A. Khan^{1*} and Akhtar Parwez²

¹ Department of Biotechnology, Chaudhary Bansi Lal University, Bhiwani, Haryana, India

² Bhuvaneshwari Dayal College (B.D. College), Patna, India

Abstract: Nitric oxide (NO) is a universal, water-soluble, free radical gas, which plays an important role in the physiological along with pathological processes. NO has been shown in the literature as a key player in carcinogenesis as well as tumor development. Still, there is a lot of debate and misunderstanding about its involvement in cancer. It is believed to have both tumoricidal as well as tumor-promoting effects, which are determined by its timing, location, and concentration. NO has been linked to angiogenesis, apoptosis, cell cycle, invasion, and metastasis. On the other hand, it is emerging as a possible anti-oncogenic agent. Strategies for manipulating *in vivo* production and exogenous delivery of this molecule for therapeutic gain are being investigated. For therapeutic advantage, strategies for controlling *in vivo* synthesis and exogenous distribution of this molecule are being investigated. Further research in experimental settings and clinical trials is required to enhance innovative NO-based cancer prevention and treatment strategies. The spectrum of NO actions in cancer and the mechanisms by which NO acts in breast cancer are addressed in this article.

Keywords: Nitric oxide, Nitric oxide synthase, Reactive nitrogen species, Tumoricidal.

INTRODUCTION

Cancer is the second leading cause of mortality in the world. Worldwide cancer accounts for about one in six deaths [1]. Globally, an estimated 1.5 million women are affected by breast cancer each year [2]. Breast carcinoma is the most frequently diagnosed malignancy and the second-most leading cause of cancer death among women.

Palmar discovered that epithelium cells synthesized nitric oxide from L-arginine in 1987 [3]. In mammalian cells, it is synthesized endogenously by the NOS (nitric oxide synthase) enzyme, is short-lived, and performs various physiological

* Corresponding author Ekhlaque A. Khan: Department of Biotechnology, Chaudhary Bansi Lal University, Bhiwani, Haryana, India; E-mail: ekhlaquebiotech@gmail.com

processes as signaling molecules. Nitric oxide gas produced in the body serves as a signaling molecule.

Unregulated and excessive nitric oxide production has been implicated as a cause of pathophysiological processes, including carcinogenesis. Nitric oxide synthase has been detected in many types of cancer like breast, uteri cervix, head and neck, laryngeal, and CNS (central nervous system) cancer [4 - 7]. Nitric oxide is thought to affect a variety of cancer-related processes [8]. Many research findings advocated that nitric oxide plays a dual role in carcinoma. At measurable levels in different types of clinical samples, nitric oxide supports tumour growth and proliferation. On the other hand, it has been demonstrated that nitric oxide has tumour effects. Many indirect and direct effect molecular mechanism pathways have been proposed for its antitumor characters [9, 10], but there is a lack of data on cancer patients. The tumoricidal characters of nitric oxide are being investigated for therapeutic purposes. Nitric oxide is used alone or in grouping with another cytotoxic agent [11].

Breast cancer is a complex malignancy with a heterogeneous expression of PR (progesterone receptor), ER (estrogen receptor), and HER2 (human epidermal growth factor) in patients, resulting in intratumoral and intertumoral heterogeneity, histology prognosis, and treatment responsiveness [12, 13]. The deviation in a transcriptional program, which could aid in providing a unique molecular profile for each tumor, is the main reason for the strong heterogeneity [12, 14]. Young women have been diagnosed with early breast cancer with an aggressive phenotype, necessitating the implementation of a breast cancer awareness and screening program [15]. An imbalance in the rate of production and removal of ROS (reactive oxygen species) or RNS (reactive nitrogen species) is known to cause oxidative stress. Reactive species can play a dual role, causing oxidative damage (as acting as molecular signals) and activating stress responses, all of which are beneficial to organisms [16]. Through pleiotropic effects on cell targets, reactive nitrogen species play an important role in cellular physiological regulation. A high level of RNS causes nitrosative stress, which has been linked to cell death and injury [17].

Nitric oxide acts as a signal molecule in different parts of the body as well as a cytotoxic or regulatory effector molecule in the innate immune system. Following enzyme activation of constitutively expressed eNOS (endothelial nitric oxide synthase) or nNOS (neuronal NO synthase), signal molecules of nitric oxide are synthesized on demand for brief periods (seconds to minutes). On the other hand, after cell activation, iNOS (inducible nitric oxide synthase) is expressed and produces nitric oxide for a long time (an hour to days). However, the controlled production of constant nitric oxide compared with the pulsative synthesis

distinguishes the pathophysiological and physiological action of nitric oxide.

All reactive nitrogen species (RNS) share a common, primary progenitor, and some RNS are made up of NO-dependent reactions. ONOO (peroxynitrite) and N₂O₃ (dinitrogen trioxide) are reactive nitrogen species that can cause oxidative and nitrosative chemical stress [18, 19]. A quick reaction between O² and NO produces ONOOH⁻ (peroxynitrite), which is then converted into secondary RNS by another reaction. RNS reacts with nitric oxide (NO) and its intracellular environment to produce other reactive metabolites such as nitrite, S-nitroso-thiols, and peroxynitrite, all of which have genotoxic effects and cause DNA damage [20]. By targeting the sugar-phosphate backbone of DNA, peroxynitrite species can split the DNA into single-stranded [20].

Physiological and Biological Action of Nitric Oxide

Nitric oxide plays a crucial role in various biological processes like macrophage-mediated immunity, vasodilatation, and neurotransmission. Nitric oxide is a great reactive diatomic and diffusible free radical and is present at room temperature in gaseous form and has pleiotropic functions. Moreover, it can act as a messenger of molecules and participate in promoting and inhibiting carcinoma [12, 20]. Nitric oxide is a short-lived endogenously produced gas that acts as a signaling molecule in the body. It is synthesized by the nitric oxide synthase (NOS) enzyme, which is endogenously produced by mammalian cells at an appropriate time and magnitude. Overexpression of NO synthesis has been associated with many pathophysiological conditions including carcinoma. NOS expression is identified in several cancers like breast, uteri cervix, CNS (central nervous system), head and neck, and larynx cancer [4, 19]. NO has been shown to modulate various carcinoma-associated events [8]. NOS enzyme is ubiquitously expressed in cancer and helps in the NO synthesis in the presence of O₂ from L-arginine [12]. NOS required FMN, FAD, NADPH, and BH₄ [(6R-) 5, 6, 7, 8-tetra-hydrobiopterin] as cofactors. NOS1, NOS2, and NOS3 are three distinct genes encoding isoforms of NOS in mammalian cells, with 51-57 percent homology in regulation, localization, inhibitor sensitivity, and catalytic properties. NOS1 is classified as an isoform first purified and cloned from neuronal tissue (nNOS), while the isoform first found in endothelial cells (eNOS or NOS₃) is known as constitutive because it is expressed continuously in endothelial cells and neurons, respectively. Multiple factors, including interferon (IFN), interleukin (IL-1), tumor necrosis factor (TNF), oxidative stress, and bacterial endotoxin, can inhibit or trigger eNOS and nNOS expression through protein kinase-mediated phosphorylation whereas iNOS expression can be regulated transcriptionally by multiple factors, including interferon (IFN), interleukin (IL-1), tumor necrosis factor (TNF- α) and bacterial endotoxin such as lipopolysaccharide (LPS) [12].

CHAPTER 6**Autoantibodies as Clinical Biomarkers in Breast Cancer****Prachi Gupta^{1,*}**¹ *Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA*

Abstract: Breast cancer (BC) is one of the most diagnosed and worldwide malignancies in females with an estimated 1,300,000 new cases and 465,000 deaths annually. Therefore, early diagnosis and effective treatments of BC are urgently needed in the struggle against this disease. Molecular markers research has gained huge momentum in BC management. Very few molecular markers are in clinical use for BC management. However, owing to BC heterogeneity, more molecular markers are required for better diagnosis and treatment. Humoral immune response defines the generation of autoantibodies (AABs) in blood against tumor-associated antigens (TAAs). Such AABs have been showing great promises for biomarker development for cancer detection. Therefore, these candidate AABs might be useful for developing blood-based detection assays along with other existing diagnostic tools for BC patients. Besides that, AABs can also assist in the identification of novel TAAs that can further enhance the utility of immuno-proteomics for biomarkers development and targeted therapy. In this scenario, proteomics tools are being extensively utilized to identify novel TAAs.

Keywords: Autoantibodies , Autoantigens , Biomarkers , Early detection of cancer , Tumor-associated antigens .

INTRODUCTION**Biomarkers**

Biomarkers are defined as biomolecules that can be found in biofluids or tissues and can predict the occurrence of any condition normal or abnormal like disease onset, disease progression, and treatment response. Any type of biomolecules can serve as biomarkers if they can differentiate between normal vs. abnormal conditions with certain specificity and sensitivity [1]. Several biomolecules like cells, Proteins, nucleic acids like RNAs and DNAs, metabolites, and antibodies

* **Corresponding author Prachi Gupta:** Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Tel: ?????; E-mail: prgupta@mcw.edu

have been defined in the literature so far. Biomolecules can be found in any biological material like blood, stool, urine, nipple discharge, or tissues. Biomarkers can be accurately identified in diseased conditions and can work as clinical biomarkers as they can be utilized for diagnosis and prognosis of the disease. This ability of biomarkers has been appreciated well in cancer research as several biomarkers have been known to clinically diagnose cancer at early stages. Biomarkers are also useful to monitor therapy response and recurrence of cancer.

Breast Cancer Biomarkers

Breast cancer is a heterogeneous disease defined by various subtypes. Heterogeneity in breast cancer led to the discovery of various biomarkers which are guiding breast cancer treatment. The most known are estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Based on these three biomarkers, breast cancer treatment has been revolutionized. Other than these, the concentration of glycoproteins like CA15.3 and CA27.29 are also helpful in monitoring disease progression [2]. Since the discovery of these protein markers, many other markers have been explored for their utility in the diagnosis or prognosis of breast cancer, however none of them have reached the clinic to date [3]. However, consistent efforts have led to the discovery of other potentially useful markers. In this consistent effort of biomarker findings, autoantibodies (AABs) emerged as an important tool for the early diagnosis of breast cancer [4].

AUTOANTIBODIES

Autoantibodies (AABs) are the antibodies against self-antigens in the body. AABs generation is a natural process in the human body. Healthy human beings contain AABs against several self-antigens which may take part in the natural defense system. Self-antigens are proteins that trigger the generation of antibodies against antigens. However, any change in self-antigens like antigen alteration by mutation, post-translational modification, overexpression, or release of intracellular antigen upon cell lysis, can further trigger the generation of AABs against self-antigens [5]. During the early events of tumorigenesis, many antigens change their natural behavior as they either show overexpression or get mutated which changes their confirmation and exposes new sequences for antibody generation [6]. Such changes can trigger the generation of AABs during the early events of tumorigenesis and thus can mark the beginning of cancer in the human body.

GOALS OF CANCER BIOMARKERS

The idea of biomarker discovery circumvents such markers which have the

following characteristics:

1. Help in the development of non-invasive that can diagnose cancer risk in its earliest stages.
2. Can categorize cancer in a way that can guide appropriate therapy and disease progression.
3. Which are stable in easily accessible samples like blood.
4. Which can easily get identified in samples with the available tool.
5. Which are less prone to proteolysis during the sample collection, storage, and processing.
6. This can help in the development of a cost-effective test.
7. Which showed better sensitivity and specificity for the diagnosis of the disease.

Thus, a plethora of search work has been done and still going on to find out such biomarkers in human blood which can fit into all these criteria.

AUTOANTIBODIES AS POTENTIAL CLINICAL MARKERS FOR CANCER

Blood plasma is the most preferable choice of sample for the identification of Tumor-associated antigens (TAAs). However, there is poor detection of antigens themselves in blood as they are present in very low concentrations in blood so the current methodology is not able to identify them. Furthermore, antigens have a short life in blood and are highly prone to proteolysis. Due to such discrepancy, AAbs seem to be the better option for biomarker discoveries than their antigens themselves.

Cancer triggers an immunologic response in the form of AAbs against TAAs. AAbs pose immense potential for early diagnosis of breast cancer. As AAbs are less prone to degradation and more stable in blood. They also show persistent responses over time as their self-life is more than TAAs. Furthermore, AAbs can be easily detected in blood by the recently available, cost-effective techniques. Besides this, the most important point of consideration for AAbs is that they produce in very early events of tumorigenesis and can be detected several years before the clinical development of cancer [7]. Therefore, AAbs can become the obvious choice for the detection of early-stage breast cancer.

To show the clinical utility as a diagnostic biomarker, AAbs should be able to distinguish breast cancer patients with high accuracy, specificity, and sensitivity. To become a good early screening marker, certain cutoff values for the AAbs should be selected to determine diagnostic accuracy in the form of high sensitivity and specificity. Diagnostic accuracy can be plotted in a receiver operating

Epigenetics of Breast Cancer

Manuraj Pandey^{1,*}, Archana Lalwani² and Rajendra Mehta³

¹ Department of Biotechnology, Unique College, Jawahar Chowk, T.T. Nagar, Bhopal, M.P. India

² Department of Botany and biotechnology, Sadhu Vaswani autonomous college, Sant Hirdaram Nagar, Bhopal, 462030, India

³ Department of Rural Technology and Social Development, Guru Ghasidas Vishwavidyalaya (Central University), Bilaspur, CG, India

Abstract: Breast cancer is a very heterogeneous disease at clinical, histological, and molecular levels. It is the leading cause of cancer-related deaths among women. Breast cancer is manageable if diagnosed early at a localized stage, but late diagnosis of metastatic disease has a very low patient survival rate. Further, limited treatment options, insufficient prognostic and diagnostic markers, misdiagnosis and drug resistance pose a greater problem for patient survival and clinical outcome. Consequently, there is a great need to explore newer and more effective diagnostic, prognostic and therapeutic options for managing breast cancer. It is now a well-known fact that along with genetic changes, epigenetic modifications play an important role in the origin and pathogenesis of breast cancer. Universal involvement of epigenetic modifications in breast cancer development makes them useful for diagnosis, prognosis, and follow-up purposes. Further, the reversibility of epigenetic changes makes them attractive targets for breast cancer therapy. Therefore, in this chapter, we will discuss current knowledge on epigenetic involvement in the development of breast cancer and epi drugs as treatment options for breast cancer management.

Keywords: DNA methylation, Epigenetics, Histone deacetylases, Methyltransferases, microRNAs.

INTRODUCTION

Cancer evolution is a multistep, complex process driven by various genetic and epigenetic abnormalities in the cell [1]. Genetic abnormalities involve gene mutations, chromosomal alterations which can be structural or numerical and which are rare in normal cells but are prominent in the tumor cells [2]. Genetic abnormalities are heritable changes in DNA sequences that can alter the gene

* Corresponding author Manuraj Pandey: Department of Biotechnology, Unique College, Jawahar Chowk, T.T. Nagar, Bhopal, M.P. India; E-mail: manuraj4b@gmail.com

expression and genomic stability in a cancer cell, whereas epigenetic changes are heritable, which alters the expression of genes without altering the DNA sequence [3].

Epigenetic changes cause silencing of tumor suppressor genes (TSGs) and activation of oncogenes in a cancer cell [4]. Epigenetic changes involve DNA methylation which occurs at the 5th position of cytosine at CpG dinucleotide sequences and modification of histone proteins by covalent changes like phosphorylation, acetylation, and methylation, which alter cellular gene expression without changing DNA sequences [5]. In the past two decades, microRNAs, a group of noncoding RNA, have also been accepted as an epigenetic modulator as these regulate post-transcriptional modification [6, 7]. There are more accepted and recently described modifications, including nucleosome positioning, chromatin remodeling, and chromosomal looping [8 - 10]. All epigenetic modifications are strongly linked, and can easily induce one another [8]. Local CpG hypermethylation at promoter regions silences TSGs expression, whereas global hypomethylation increases genetic instability. Histone modifications affect the packing of genetic material which consequently alter gene expression by changing the accessibility of transcription factors at promoter or enhancer sites [11, 12]. Among all types of cancers, breast cancer is the most common type of cancer among women and the second most common cancer after lung cancer. Breast cancer affects millions of women worldwide. It is a leading cause of cancer-related deaths among women and causes a significant economic burden [13]. In recent years, various diagnostic and treatment options have been explored to manage localized and metastatic breast cancer. Combined epigenetic therapies show enormous potential in the management of breast cancer. Tremendous efforts have been put forward by researchers in the past decades to resolve the intricate relationship of epigenetics involvement in the development and progression of breast cancer. But still, there is a massive gap in the understanding of complex interactions between epigenetics modifications and breast cancer. Therefore, a better understanding of breast cancer epigenetics is needed to explore its immense potential to manage breast cancer. In this chapter, we will discuss epigenetic modifications, their involvement in breast cancer pathogenesis, and exploiting epigenetic modulation as treatment options.

EPIGENETIC PROGRAMMING AND CELLULAR PHYSIOLOGY

Epigenetic changes are important for the development, maintenance, survival, and specific functions of a cell. Some important developmental events like patterning by Hox genes, X-inactivation, neuronal development, and genomic imprinting are regulated by epigenetics [14]. Each and every cell has its own epigenetic blueprint which is then inherited by its progeny. DNA methyltransferases (DNMT's) and

histone modifiers (Table 1) maintain these blueprints during cell division and restore the function of specific cell types or tissue [3]. Epigenetic imprinting also functions as an epigenetic memory for a cell [15]. Various molecules are involved in maintaining the epigenetic makeup of a cell. DNA Methyltransferases (DNMT1, DNMT3a, and DNMT3b) are enzymes that methylate DNA at the CpG dinucleotide sequence. DNMT1 is the maintenance enzyme that regulates the methylation blueprint of a cell after replication whereas DNMT3a and 3b are de-novo methyltransferases that generate new methylation patterns and actively participate in developmental processes [16].

Table 1. Epigenetic regulators that maintain epigenetic blueprint of a cell.

| Epigenetic Modification | Category of Enzymes | Enzymes | Function |
|--|------------------------------------|-----------------------------|--|
| DNA modification (DNA methylation) | DNA methyltransferases | DNMT1, DNMT3a/3b/3l | Gene silencing, chromatin organization, stable heritable modification, X-chromosome inactivation, imprinting, silencing of repetitive elements |
| | DNA demethylases | TET, AID, MBD2/4 | |
| Histone modification (Methylation Demethylation Acetylation Deacetylation) | Histone methyltransferases (HMTs) | PRMTs, EZH2, SUV39h1, SYMD3 | Heritable labile modification, activation or repression of gene transcription, chromatin structure and nucleosome positioning |
| | Histone demethylases (HDMs) | LSD, JMJD, JDHM | |
| | Histone acetyl transferases (HATs) | Tip60, MOZ, MORF, CBP, p300 | |
| | Histone deacetylases (HDACs) | HDAC1-11, SIRTs | |

Methyl binding domain proteins (MBD's- MBD1, MBD 2, MBD 3, MBD 4, and MeCP2) read methylation marks and help to make repressor complexes [17 - 19]. Histone proteins maintain chromatin structure and its dynamics. Histone modifiers act on amino acids at the histone tail and change their affinity toward chromatin. Histone modifying enzymes are histone acetylases, histone deacetylases (HDACs), histone methyltransferases (HMTs), phosphorylases, and sumoylation enzymes. Polycomb proteins that were identified in *Drosophila* make repressor complex PRC1 and PRC2 which modifies histone at specific positions and direct DNA methylation. EZH2 is an important member of PRC2 and functions as histone methyltransferases [20 - 22].

Epigenetic Modifications are Strongly Interlinked

Although it has been observed in the in-vitro system, DNA methylation can alone

CHAPTER 8**Nanoparticles Targeting and Uptake: Current Advances in Breast Cancer Research****Onila Lugun¹ and Alok Kumar Pandey^{1,*}**

¹ *Nanomaterial Toxicology Laboratory, Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvighyan Bhawan, 31, Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India*

Abstract: With the rapid advancement, nanoparticles (NPs) based drug delivery systems have been recognized as expedient over traditional therapeutics for breast cancer, fostering targeted drug release, long circulation time, reduced toxicity, and greater bioavailability. Under normal circumstances when this exogenous structure of nano-scale dimension approaches nearby cells, it evokes early tripping leading to membrane wrapping and NPs cellular uptake. Tailoring NPs structure for safe and intended entry into cells is at the core of nano-therapeutics for attaining high-yield prognostic and therapeutic efficacy. Interestingly NPs uptake is crucial as it unravels pathway selection and is decisive for the intracellular fate of nano-medicine. Over the past, it remained a major challenge to target specifically to improve their delivery. A significant effort has been devoted to understanding the endocytosis of nano-medicine for efficient intracellular delivery of NPs. Here we present an overview of the different endocytic pathways used by cells. Novel strategies in NPs design to exploit the uptake mechanisms to decipher intended uptake and target breast cancer. Current advances and strategies are deployed to breach these barriers and attain the ultimate vision of nano-carriers in diagnostics and therapeutics.

Keywords: Endocytosis, Nano-carrier, Nanoparticles, Targeted Therapeutics.

INTRODUCTION

Breast cancer is the primary reason for the growing fatality rate among all cancers in females around the world with close to 60% of deaths taking place in developing Countries [1]. According to recent reports, breast cancer as of today is the most commonly visualized in both developed and developing countries [2]. Incident rates were recorded in different parts of the world with varying rates. Per 100,000 women 19.3 cases were recorded in Eastern Africa and 89.7 cases in Western Europe with an overall average of greater than 80 in developed regions

* **Corresponding author Alok Kumar Pandey:** Nanomaterial Toxicology Laboratory, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvighyan Bhawan, 31, Mahatma Gandhi Marg, Lucknow, Uttar Pradesh, 226001, India; E-mail: alokpandey@iitr.res.in

of the world and 40 in developing regions. This will increase the world's breast cancer burden in the future. Collective efforts are underway to lessen the global incidence of disease and increase the survival rate in breast cancer incidences with cost-effective interventions. Varying contemporary medicines are recommended to cure breast cancer, but the main impediment associated with this is its heterogeneous nature encompassing multiple subgroups with different cellular composition, molecular signature, prognoses, dissemination patterns, and responses to therapies. The nanoparticles (NPs) carrier system represents a promising therapeutic vehicle for the transportation of anticancer drugs in diseases like breast cancer. However, the main challenge encountered in the delivery system is the targeted delivery to the specific cancer site within the complex tumor microenvironment. These nanocarrier systems due to their unique size to surface ratio show enhanced drug-carrying capacity, controlled drug release profile, and overcome various biological barriers to confer target drug delivery. These tailored NPs include therapeutic compounds loaded in NPs, with increased release kinetics, and are expected to be released intracellular to achieve efficacy. Because of their unique size, though NPs act as a good delivery carrier, but the poorly organized vascularization system, and increased pressure within the tumor microenvironment limits the easy entry of particles inside the system. Hence targeting specific cells and uptake efficiency of the delivery vehicle into the tumor cells is imperative for predicting the therapeutic performance of nanomedicine. To address this major quest various targeted delivery of nano-therapeutics has been designed to confer enhanced circulation time, cellular uptake, improve therapeutic efficacy, and decrease systemic toxicity. Here the current developments in targeted nano-carrier systems specifically for breast cancer are envisioned with special emphasis on different endocytosis mechanisms.

INTERNALIZATION PATHWAYS

NPs-based drug delivery strategies have arisen as a desirable vehicle for drug transport throughout the body by overcoming the problems associated with conventional drug formulations. However, prior to targeted delivery of any therapeutic, it is a prerequisite to overcoming several transport barriers for efficient accumulation of nano-therapeutics at the diseased location. To achieve a proper therapeutic outcome, the transport of NPs across the plasma membrane has been imperative. Substantial research efforts have aimed to understand the detailed mechanism of NPs internalization for competent cargo transport. Plasma membrane forms a barrier from the surrounding environment and provides a protective milieu for various physiological processes. Apart from this, it plays a role in cellular adhesion, endocytosis, and communication. Endocytosis largely encompasses intracellular membrane-enclosed vesicles formed mostly by the cell

membrane invagination made up of internalized cargo along with extracellular fluids. When NPs arrive at the surface of cells, they maintain contact with various constituents of the plasma membrane and through endocytosis are internalized by the cells. It is frequently observed that the low molecular weight and hydrophobic molecules easily permeate across the membrane; however, micro- and nano-particles employ active internalization procedures [3]. In the case of NPs receptor-mediated endocytosis is the main uptake pathway, which is governed by the binding of cell surface receptors with molecules linked to the surface of NPs. Endocytosis is a very dynamic and regulated process with different variants being dependent on the cell type and cargo transported. Several uptake processes are present for the cellular internalization of NPs including phagocytosis, clathrin, caveolae-dependent, clathrin- and caveolae independent endocytosis and macropinocytosis but broadly internalization by means of endocytosis is of two types of namely phagocytosis and pinocytosis. Prior to the strategies in designing targeted nano-medicine capable of efficiently targeting breast cancer a detailed understanding of the different endocytic pathways is needed. Hence, comprehensive overviews of the different endocytic pathways are described below.

PHAGOCYTOSIS

Endocytosis mediated through phagocytosis is a characteristic of professional phagocytic cells like macrophages, dendritic cells, monocytes, and neutrophils, employed in host defense mechanisms associated with both innate and adaptive immunity and clearance of cell debris. Apart from these, a few other cells also show phagocytosis (fibroblasts, basophils, eosinophils, mast cells, natural killer cells, epithelial and endothelial cells) but only to a very low extent [4, 5]. Phagosomes formed for the engulfment of any entity can span up to >250 nm [6]. Phagocytosis can be stimulated either through the interaction of ligands already present on the surface of a foreign entity with cell surface receptors or soluble factors that bind and help recognize that entity to cells (opsonization). Mostly in the case of NPs phagocytosis is triggered through opsonization of soluble factors which includes complement proteins, immunoglobulins (antibodies), or other blood proteins (acetylcholine, fibronectin, laminin, c-reactive protein, and type-I collagen) [7]. Mostly the receptors involved to elicit phagocytosis are Fc receptor family (FcγRI, FcγRIIA), mannose/fructose receptor, complement receptors (CR1, CR3, and CR4), scavenger receptor, and α5β1 integrin receptor [8].

Processes involving NPs internalization *via* phagocytosis have been extensively explored to design particles for regulating phagocytosis and intracellular targeting. Recently it was found that particle geometry has been a major impetus for internalization *via* phagocytosis [9]. Particles assisting surface receptor-

Dietary Polyphenols and its Molecular Mechanism in the Management of Breast Cancer

Girish Rai^{1,*}, Sudhir Kumar Shekhar^{2,3} and Sarfraj Ahmad Siddiqui⁴

¹ Vivekanand Government PG College Maihar, MP, India

² Department of Biochemistry, King George Medical University, Lucknow, India

³ Centre of Biomedical Research, SGPGIMS Campus, Lucknow, UP, India

⁴ Department of Zoology, University of Lucknow, Lucknow, India

Abstract: Despite clinical and pharmacological advancement in medical science breast cancer has become a global concern due to the high mortality rate. Breast cancer is mainly associated with altered redox status, cell cycle, chronic inflammation, and increased proliferative rate. Breast cancer has various molecular subtypes and adequate knowledge of these altered cell cycle regulatory cascades and molecular subtypes of breast cancer is a must for proper prognosis and its successful treatment. The discovery of drugs with anticancer properties, particularly against the specific subtype of breast cancer has become a challenging task for cancer researchers. Dietary polyphenolic compounds as cancer chemopreventive agents have drawn much attention among researchers because polyphenolic compounds are natural in origin with lesser side effects and have a wide range of action against various subtypes of breast cancer. Dietary compounds with antioxidant properties have been reported to act on an array of genes and proteins associated with breast cancer pathogenesis and thus regulate the signaling cascade related to autophagy, chronic inflammation, apoptosis, and cell cycle regulation. All in all, these natural compounds regulate growth and progression of a tumour with less or no side effects. Thus, the current article focuses primarily here on various aspects of breast cancer and food polyphenolic compounds as well as their molecular mechanism for managing breast cancer.

Keywords: Epigallocatechin gallate, Polyphenols compounds, Quercetin, Resveratrol, ROS.

INTRODUCTION

In the current scenario, cancer has become one of the most common life-threatening evils across the globe. Breast cancer is most common among women and each year out of 1.4 million breast cancer incidents 450000 leads to death. It

* Corresponding author Girish Rai: Vivekanand Government PG College Maihar, MP, India; E-mail: girishrai14@gmail.com

is assumed that one in eight women will have breast cancer during their lifespan [1]. There are four universal strategies to regulate different stages of carcinogenesis [1 - 3]. The first one is the cancer chemopreventive approach which effectively modulates the carcinogenic and mutagenic effect and consequently, inhibits initiation and promotion steps in tumor formation. The second and most effective approach is to involve such a strategy that prevents early stages of carcinogenesis *via* modulation of signal transduction, blocking angiogenesis, antioxidant mechanisms, and altering immunity, which finally results in the blockage of cancer progression and chemoprevention. The third strategy to tackle cancer treatment is to control the metastatic potential in the tumor by targeting the proteins and genes such as regulating the epithelial-mesenchymal transition in the tumor [1, 2]. The fourth one is the surgical approach for breast cancer, which is very invasive and exhibits the probability of cancer recovery.

Cancer researchers are in search of promising and targeted drugs having lesser side effects, for breast cancer management [4]. Dietary compounds which are secondary metabolites from different sources such as plants [5], microbial [6], and marine species [7] have proved their efficacy against various types of cancer including breast cancer and other types of disease and disorder. Among various dietary compounds, the polyphenols have emerged as one of the promising compounds having great potential for the management and prevention of various types of disease and disorders such as cancer [8 - 13], diabetes [14, 15], inflammation [16 - 19], obesity-associated diseases [20], neurodegenerative disorders [21 - 23], bacterial [24 - 27] and viral infections [28, 29] or cardiovascular diseases [30]. In addition, these polyphenolic compounds have potent antioxidant activity and can target an array of genes and proteins and thus signaling cascade altered during carcinogens and various types of neurological and inflammatory disorders [31 - 35].

Polyphenolic compounds are found in high concentrations in fruits, vegetables, tea, spices, and their molecular structures are characterized by the presence of one or more phenolic rings substituted with at least one hydroxyl group. Phenolic acids, flavonoids, and lignan stilbenes are the main group of phenolic compounds. Polyphenols have potential anticancer activity, including breast cancer, they are multifaceted compounds and have been demonstrated to target an array of genes and proteins associated with apoptosis, metabolic pathway, angiogenesis, epithelial-mesenchymal transition (EMT), and cell cycle regulatory as well as inflammatory cascade [36]. The multi-targeted activity of these dietary polyphenols against cancer, including breast cancer is mainly due to their antioxidant activity. This antioxidant activity imparts and alteration of an array of proteins, enzymes, and membrane receptors, resulting in regulating gene

expression, apoptosis induction, vasodilatation, and modulation of the cell cycle in cancer [37 - 42]. In addition, these dietary polyphenols have cancer chemopreventive effects against tumor initiation through numerous mechanisms, such as the inhibition of carcinogenic molecule formation, blockade of oncogenic transforming enzyme activity [43], regulation of phase I and II enzymes, such as cytochrome P450s(CYP) [44] and S-transferase (GST) [45], as well as preventing DNA damage in the cells [46, 47]. For all these reasons, new treatments based on polyphenolic compounds are being studied as an alternative and/or adjuvant therapies in these pathologies using different breast cancer models [21]. The potential benefits of their dietary intake on human health and, more specifically, on cancer risk (including breast cancer) have been also reviewed [48, 49]. Specifically, for breast cancer, interesting results have been obtained with a mixture of tea extract and quercetin [50], with *Pinus radiata* [51], Indian lotus [52], *Hypogymniaphysodes* lichen [53], *Morindacitrifolia* [54], or with olive leaf extracts [55 - 58], among others. In this book chapter, we will discuss the types of breast cancer, including biomarkers associated with it and therapeutics associated with it.

Breast Cancer: An Overview

Breast cancer is a more dreadful and heterogeneous group of diseases and accounts for the second most diagnosed cancer after lung cancer. As compared to the global rate of incidents of death associated with cancer, breast cancer ranks the fifth position among all types of cancer. According to a Globcan report, 1.7million women were diagnosed with breast cancer in 2012, and in previous years, the incidence of breast cancer has increased by 20%, while the rate of mortality has increased by 14%. Moreover, breast cancer is the most common cause of death and frequently diagnosed cancer in women among 140 out of 184 countries worldwide. Although breast cancer is the frequently diagnosed cancer in developed countries, Globocan's cancer data also add a high mortality rate in developing or less developed countries. The incidence of breast cancer is to some extent because of changes in lifestyles, as well as the lack of clinical advances to breast cancer patients living in these regions. The current data on breast cancer evidenced that the rapid social and economic changes, the altered lifestyles of industrialized countries lead to an increased burden of cancers associated with reproductive, dietary, and hormonal risk factors may be the stipulated reason for increasing trends of breast cancer incidence among developing countries. The comparative analysis of data among developed and developing countries showed that the incidence rates remain highest in more developed regions, but mortality is relatively much higher in less developed countries, which is due to a lack of early detection and access to treatment facilities.

Radiotherapy in Carcinoma Breast

Teerthraj Verma^{1*}, Mranalini Verma¹ and Ratnasekhar Ch²

¹ Department of Radiotherapy, King George's Medical University, UP Lucknow; India

² CSIR-Central Institute of Medicinal and Aromatic Plants Lucknow, India

Abstract: Radiotherapy therapy is one of the effective and curative methods for the treatment of cancer. One of the reasons for the growing popularity and increased outcome of radiotherapy is attributed to the tremendously enhanced capacity of detection and imaging quality with the reduced radiation dose. Breast cancer is the leading cause with the highest percentage incidence in women worldwide and is the leading cause of cancer death, especially in the developing world. Over 50% of breast cancer patients have been prescribed radiotherapy during their cancer disease management. The present chapter discusses a comprehensive approach to the role of radiotherapy in breast cancer, including the theory, different phases, and types, clinical aspects as well as the challenges involved in its optimal outcome. Chemotherapy, hormone therapy, *etc.*, are the primary treatment modalities for breast cancer, outside of surgery. In this chapter, external beam radiation treatment is mainly discussed.

Keywords: 3-Dimensional conformal radiotherapy, External Beam Radiotherapy, Intensity-modulated radiation therapy, Medical LINAC, Virtual Simulation.

INTRODUCTION

Radiotherapy therapy is one of the effective methods for the treatment of cancer. In this process, ionizing radiation is delivered with the primary intention to kill the tumor cells sparing the normal cells as much as possible taking into account tumoricidal and tissue tolerance dose [1, 2]. With continuous technological improvement in cancer treatment, high-energy x-ray and gamma photon beams of the order of MeV or MV are being used. Apart from its use for the treatment of cancer cells, radiotherapy is also useful for a few non-malignant benign conditions. Sometimes it is used in combination with surgery, chemotherapy, or hormone therapy [3, 4]. Broadly radiation therapy can be divided into two categories *viz* External Beam Radiotherapy (EBRT) and Brachytherapy (BT). The

* Corresponding author Teerthraj Verma: Department of Radiotherapy, King George's Medical University, UP Lucknow; India; E-mail: teerth05kashi@gmail.com

most common radiation beam used in EBRT is photons, but it can be of electrons, heavy ions, or some heavy particulate radiation. Radiotherapy is given either-with curative intention or with the primary aim to relieve the pain and symptoms as well as to enhance the quality of life; commonly known as palliation [5, 6].

RADIOTHERAPY: DEFINITION AND PRINCIPLE

Radiotherapy is a branch of medicine that utilizes ionizing radiation for the treatment of tumor and occasionally benign diseases, as well. Due to the hazardous nature of ionising radiation, it is delivered in a very controlled and precise manner to achieve its principle that demands maximum dose delivery to the target volume with as low as possible dose to the surrounding normal structure/normal cells. It is basically a differential response of tumor cells and normal cells towards ionizing radiation that allows the use of radiation in the treatment of cancer diseases. This fact can be understood with the help of the diagram (for the depiction only) shown in Fig. (1).




Fig. (1). Relationship between the response of both tumor, normal tissue, and radiation dose (Not to scale).

The dose range/interval between two points A and B on the dose axis are called a window where A is the dose point beyond which tumor irradiation/tumor control starts and B is the point where normal tissue complications start. The success of radiotherapy depends on this window gap also, majorly, with a wider window higher dose can be delivered to the tumor volume without having severe side effects of radiation.

As soon as radiation comes into the vicinity of human tissues, it starts to interact with the medium. In fact, radiation beams damage the deoxyribonucleic acid (DNA) of malignant cells. The double-strand break is considered to be the

endpoint, making cells undergo apoptotic mode. Once damage to the DNA of the tumor cell is achieved, then its replication is halted [7]. Sometimes the DNA of a cell is not completely or precisely damaged, resulting in a mutation.

The irradiated volume in a patient usually contains both targeted healthy and tumor tissues. DNA damage occurs in healthy cells as well as tumor cells but due to faster reproduction in normal cells and reduced repair capability of tumor cells, they are more sensitive to ionizing radiation [8, 9]. Normal cells have better capabilities to handle the damage caused by radiation exposure compared to malignant cells for the same level of damage and this improves drastically if given the adequate time provided the dose is within the tolerance limit. Thus, the success of quantifiable radiation therapy in terms of therapeutic gain (equation 1) is the direct result of the exposed dose [10, 11].

$$\text{Therapeutic gain} = \frac{\text{Tumor Control Probability}}{\text{Normal Tissue Complication Probability}} \quad (1)$$

Tumor control probability (TCP) is defined as the probability of eradication of tumor cells from the cell population, whereas normal tissue complication probability (NTCP) gives the probability of fatal damage to normal cells from the same cell population. As depicted in Fig. (1), these two probability curves lie very close suggesting a very small dose difference for favorable response both from the tumor and normal cells at the same time. This means that radiation treatment requires a very high degree of precision. Therefore, the optimal radiation dose should be administered in a way that maximizes the TCP while minimizing NTCP [12, 13].

RADIATION SOURCES IN EXTERNAL BEAM RADIOTHERAPY

As described in the section, two approaches are used, in general, in combination or alone *via* external beam radiotherapy (EBRT) and internal beam radiotherapy or brachytherapy (BT). Here in this chapter, we would be restricting to EBRT, in which radiation source is maintained at some distance from the tumor. The external beam radiotherapy units (in convention) can be (i) Radioisotope based *e.g.* Co-60 and (ii) artificial radiation units such as Medical LINACs (Linear Accelerators).

Telegamma (CO-60) Unit

The history of radiation application in cancer therapy is as old as the discovery of x-rays. Many of the artificial radiation sources have been developed from time to time for cancer therapy and the same has been obsolete due to some reasons. Like

An Overview of Breast Cancer Therapy

Alkhansa S. Mahmoud^{1,2}, Zuki AB. Zakaria¹, Hazilawati HJ. Hamzah³, Tengku Ahbrizal F.T.A.⁴ and M.N. Mohd Hezmee^{1,*}

¹ Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia

² Radiobiology Department, Sudan Atomic Energy Commission, 1111 Khartoum, Sudan

³ Department of Veterinary Pathology and Microbiology, Faculty Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia

⁴ Malaysian Nuclear Agency, Ministry of Science, Technology and Innovation, Bangi, 43000 Kajang, Selangor

Abstract: Breast cancer is the most common type of cancer among females worldwide. It is a heterogeneous disease where the treatment strategies depend on several factors, such as tumor stage, menopausal status, breast cancer oncogenes (BRCA1 or BRCA2), and hormone receptor (ER, PR, and HER2) status. Treatment of breast cancer may be neoadjuvant therapy when given before surgery or adjuvant therapy when given after surgery. Adjuvant therapy is also known as systemic therapy, where the cancer cells are treated with chemotherapy, radiotherapy, hormonal therapy, and immunotherapy. In this article, we present current therapeutic strategies and discuss the types of treatments that constitute the standard of care for breast cancer.

Keywords: Hormonal therapy, Immunotherapy, Neoadjuvant therapy, Radiotherapy, Systematic therapy.

INTRODUCTION

Breast cancer is one of the common types of cancer that affects women worldwide and is a major cause of death among women. It accounted for approximately 6.6% of the total number of cancer deaths in 2018 [1]. However, the incidence of new cases of breast cancer has significantly increased in the last 25 years, and the mortality rates have also increased, especially in developing countries and low-income countries, while high-income countries recorded low mortality rates [2]. On the other hand, breast cancer in men accounts for 0.8%–1% of all breast cancers [3].

* Corresponding author Mohd Hezmee M.N.: Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia; E-mail: hezmee@upm.edu.my

Breast cancer is classified into four major subtypes according to hormone receptors (HR) status including luminal A (HR+/HER2-), luminal B (HR+/HER2+), HER2+, and triple-negative (HR-/HER2-). Two subgroups (Luminal A and B) are hormone receptors positive (estrogen receptor (ER) and progesterone receptor (PR) breast cancer. Luminal A subgroup (HR+/HER2-) is usually less aggressive than other subtypes. The Luminal B subgroup (HR+/HER2+) has a high expression of Ki67 (a proliferation marker) so Luminal B has a relatively poor prognosis. HER2+ breast cancer has overexpression or amplification of the HER2/ERBB2 oncogene and may be treated with anti-HER2 therapies. While triple-negative breast cancer (TNBC) is usually more aggressive than hormone receptor-positive breast cancer subtypes [4]. The current breast cancer therapeutic strategies include surgery, radiation therapy, chemotherapy, and hormone therapy, or the combination of all the standard therapeutic strategies [5], as well as immunotherapy [6]. The choice of therapy depends on tumor size, tumor subtypes, tumor stage, age, menopausal status, genetic factors, hormone receptor status, and HER2 status. Therapy planned before surgery is called neoadjuvant therapy, while treatment given after surgery is called adjuvant therapy [7]. The therapeutic selectivity is based on the better conception of the biology and molecular genetics in the tumor progression used for the promising treatments [8], also, early diagnosis of the breast has a better prognosis [9]. Furthermore, understanding the behavior and biology of breast cancer is important to improve treatment strategies. However, there are some shortcomings to each of the current standard therapeutic procedures [10]. In this chapter, we are discussing available methods for breast cancer treatment.

Neo-Adjuvant Therapy and Adjuvant Therapy

The neo-adjuvant approach to breast cancer is used for locally advanced diseases. It is used before tumor removal that can allow breast-conserving surgery, rather than mastectomy [11]. Neo-adjuvant endocrine therapy or neoadjuvant chemotherapy before surgery is the best option for survival for most locally advanced breast cancer patients [12]. However, radiotherapy is not usually considered neoadjuvant therapy for breast cancer. Phase III trials are using radiation therapy following surgery and adjuvant chemotherapy [13]. Adjuvant therapy includes chemotherapy and endocrine therapy. In some cases, a combination of therapeutic approaches is more beneficial such as combined of both chemotherapy and endocrine therapy. The main role of adjuvant treatment is to improve overall survival. Patients with early breast cancer undergoing adjuvant therapy are clinically free of disease and may be cured by surgery alone. The goals of adjuvant treatment are to improve overall survival. The meta-analysis has shown that recurrence and mortality were reduced by the action of adjuvant hormone therapy and chemotherapy for breast cancer [14].

Surgery

Surgery or mastectomy is the procedure that involves the removal of the breast entirely or partially, depending on the stages of the breast cancer, size, location, and behavior of the tumor [15]. The early detection and removal of the cancerous tumor can help prevent cancer metastases to other parts of the body. There are different types of mastectomy including a simple mastectomy that removes the breast tissues but not all the lymph nodes. A modified radical mastectomy removes the entire breast including both the breast tissues and most of the axillary lymph nodes. Radical mastectomy is the most extensive type of mastectomy is recommended in breast cancer metastasis, it is referred to as total mastectomy and removal of all mammary tissue [16]. Partial mastectomy also called lumpectomy is the removal of the part of the breast tumor tissue and some normal tissue surrounding breast tissues [15]. Surgery is sometimes combined with other therapies to improve the efficacy of therapy response [17]. Most patients are given radiation therapy treatment that may help to destroy the residual cancer cells [18]. Axillary lymph node metastasis is considered an important factor when it comes to breast cancer prognosis [19]. Sentinel lymph node dissection (SLND) is the standard surgical procedure that is used for axillary node-negative patients who undergo surgery as the first line of their breast cancer treatment. However, many studies also demonstrated that the rate of sentinel lymph node (SLN) is considered 93–99% with a false negative rate of 4–5%. Furthermore, if the SLN is negative for metastases, then no further axillary surgery is required, while the patients with a positive SLN undergo axillary lymph node dissection. The axillary lymph node plays a critical role and affects survival in breast cancer, and is often used to guide the systemic therapy decisions [20].

Radiation Therapy

Radiation therapy is another standard strategy that involves the administration of a high dose of radiation to kill cancer cells. Ionizing Radiation (IR), like X-rays and gamma rays, are used for the treatment of tumors because they can pass through tissues. The ionizing radiation for tumors depends on the kind of radiation, amount of dose, and dose fractionation [21]. Although radiotherapy has an effective role in treating breast cancer, there are a large number of patients who are radio-resistant to treatment. Cancer cells are not killed immediately by ionizing radiation, and a substantial number of those patients need more time to recover. Thus, ionizing radiation alone is not effective enough for the treatment of breast cancer so combined radiation therapy with other anticancer treatments is considered to be more effective against cancer types that are radio-resistant [22]. In solid tumors, radiotherapy combination can have better results rather than

SUBJECT INDEX

A

- Acids 129, 155, 176, 178, 179, 184, 185, 197, 220
 deoxyribonucleic 220
 fatty 176
 glycolic acid-co-hydroxymethyl glycolic 178
 hyaluronic 179, 185
 hydroxamic 155
 nucleic 129
 phenolic 197
 Activating wnt signaling 145
 Activation 9, 12, 13, 32, 33, 35, 37, 39, 41, 42, 110, 113, 141, 142, 143, 148, 204, 248, 251
 enzyme 110
 mTOR 204
 targeting 35
 transcriptional 148
 transposable element 142
 Activator 7, 251
 metastatic 7
 Activity 13, 22, 25, 36, 37, 38, 72, 74, 112, 114, 116, 117, 148, 149, 150, 197, 198, 201, 202, 203, 205, 222
 anti-metastasis 149
 antioxidant 197
 caspase 112
 catalytic 72
 cytostatic 202, 203
 lytic 37
 macrophage cytotoxic 13
 metabolic 201
 oncogenic transforming enzyme 198
 pathophysiologic 36
 pro-tumorigenic 37
 transcriptional 150
 tumor suppressor 148
 Adenocarcinoma 233
 Adenoviral vectors 119
 Adipocytes 8, 176
 Adjunct 198, 226, 233, 242, 243, 247
 radiotherapy 226
 chemotherapy 243
 radiation therapy 233
 tamoxifen treatment 247
 therapy 198, 242, 243, 247
 Adriamycin cyclophosphamide (AC) 246
 Agents 36, 70, 74, 75, 109, 115, 120, 196, 200, 206
 alkylating 70, 74
 anticancer 70, 206
 anti-estrogen 200
 anti-inflammatory 115
 anti-oncogenic 109
 anti-tumor 36
 chemopreventive 196
 mono alkylating 70
 AKT 204, 250
 kinase 204
 pathway 250
 Alcohol 115, 116, 184, 200
 dehydrogenase 200
 polyvinyl 184
 Ameliorate neutropenia 39
 Amino acids 141, 181
 targeting ligand 181
 Amphiphysin 174
 Analysis 93, 99
 bioinformatics data 93
 proteincentric 99
 Androgens 22, 24, 25, 26, 27, 28, 30, 31, 32, 38, 39, 41, 42, 43
 and innate immune system 39
 immunosuppressive role of 39
 responsive element 30
 signaling 43
 Angiogenesis 7, 8, 9, 109, 113, 116, 117, 118, 178, 182, 197
 blocking 197
 factors 7
 regulation 113
 Anthracycline chemotherapy 246

Anti-angiogenesis 7
Anti-apoptosis 151
Antibodies 38, 129, 130, 155, 173, 178, 180, 183, 188
 dependent cell cytotoxicity (ADCC) 38
Antibody-dependent cell cytotoxicity 33
Anticancer 172, 206
 activity 206
 drugs 172
Antigen(s) 10, 11, 12, 13, 33, 34, 38, 40, 129, 130, 131, 132, 135, 152, 249, 251
 cytotoxic T-lymphocyte 249
 lymphocyte 251
 presenting cells (APC) 11, 12, 33, 152
 processing 13, 40
 tumor-associated 12, 33, 129, 131
Anti-phagocytic signals 184
Anti-tumor 10, 11, 75, 250
 activity 10, 11
 effects 75, 250
Apocrine 22, 199
 breast cancer 22
 carcinoma 199
Apoptosis 7, 8, 23, 112, 119, 150, 151, 153, 178, 179, 180, 182, 183, 203, 205, 206
 pathways 119
 protein 203
Aromatase 3, 25, 38, 236, 247, 248
 inhibitors 3, 65, 236, 247, 248
AR signaling 25, 40
 for neutrophil activity 40
Atherosclerosis 202
The Atlas of non-coding RNA in Cancer (TANRIC) 99
ATM inhibitors 75
ATR 72, 74, 75, 249
 main replication stress sensor 74
Atypical ductal hyperplasia (ADH) 1, 145, 146
Autophagy 203, 204
 activation 204
 process 203
 signaling cascade 204

B

Basal-like breast 87, 90, 134
 cancer 90, 134
 tumors 87
Base excision repair (BER) 69
BC 31, 129, 135, 148, 152
 carcinomas 31
 heterogeneity 129, 152
 invasion and metastasis 148
 plasma biomarker discovery 135
Bioinformatics 86, 87, 91, 92, 93, 94, 98, 101
 analysis 94
 applications 86
 methods 86, 87, 91, 92
 tools 92, 93, 94, 98, 101
Biomarker(s) 75, 92, 100, 115, 117, 129, 130, 131, 135, 151, 152, 156, 198, 235
 epigenomic 156
 non-invasive serum 135
 novel cancer 92
 of cancer 151
Blood 1, 24, 117, 129, 130, 131, 132, 135, 173, 185, 205
 plasma 131
 proteins 173
 vessel growth 24
Bloom helicase syndrome 69
Bone morphogenetic proteins (BMPs) 37
Brachytherapy 219, 221, 234
Brain 117, 154, 155, 226
 metastasis 226
 tumor 117, 154, 155
BRCA1 1, 5, 62, 67, 68, 69, 71, 72, 133, 134, 143, 145
 gene mutations 5
 germline mutant breast cancer 71
 interacting protein 69
 mutant breast cancers 72
 mutated breast cancer 71
BRCA2 62, 67, 69, 71, 72, 73, 89, 133, 134, 143, 242
 deficient breast cancer cells 73
 genes 1, 68

Subject Index

- in breast cancer 73
- mutated breast cancer 71
- tumor suppressor genes 89
- BRCA2 mutations 67, 68, 70, 144, 200
 - heterozygous 70
- Breast 1, 8, 13, 24, 150, 229
 - hyperplasia 13
 - microenvironment 8
 - neoplasm 1
 - radiotherapy 229
 - tumorigenesis 24, 150
- Breast cancer 1, 2, 4, 22, 38, 42, 87, 88, 101, 117, 140, 145, 151, 152, 187, 204, 205, 242, 244
 - cell proliferation 42
 - deaths 204
 - detecting metastatic 152
 - dynamics 87
 - epidemiology 22
 - malignant 38
 - malignancy 1
 - metastasis 2, 4, 145, 244
 - omics data 101
 - oncogenes 242
 - pathogenesis 140, 151, 196
 - post-menopausal 64
 - progression and invasion of 151
 - prognosis 244
 - tissues 8, 117, 152
 - transformation 205
 - treatment-resistant metastatic 88
 - xenografts 187
- Breast cancer tumor 12, 35
 - cells 12
 - microenvironment 35
- Breast carcinogenesis 148, 205
- Breast carcinoma 109, 117, 199, 201
 - hormone-dependent human 27
 - lobular 6
 - tissue 25
- Breast tissues 1, 4, 13, 14, 23, 25, 117, 199, 244
 - pre-malignant 13
- Breast tumor(s) 8, 11, 12, 27, 146, 147, 152, 199, 200, 233, 244, 248

Breast Cancer: Current Trends in Molecular Research 261

- immune-suppressive 12
- tissue 12, 244

C

- Cancer(s) 3, 6, 7, 8, 10, 22, 23, 25, 31, 32, 33, 35, 36, 68, 69, 70, 72, 90, 91, 93, 95, 96, 98, 99, 109, 114, 115, 116, 131, 140, 143, 148, 149, 151, 153, 154, 155, 179, 180, 181, 182, 183, 197, 198, 199, 206, 220, 228, 244
 - angiogenesis-dependent 7
 - diseases 220
 - cervical 24, 114
 - colorectal 180
 - esophagogastric 91
 - gastrointestinal 181
 - hereditary non-polyposis colorectal 69
 - human colorectal 114
 - imaging archive 95
 - immunoediting 22, 33
 - lung 116, 140, 181, 198
 - malignancies 182
 - malignant 180
 - metastases 6, 244
 - neck 115, 116, 154, 181
 - omics data 98
 - pancreatic 155, 181
 - prostate 25, 31, 155
 - proteome atlas 96, 99
 - radiotherapy 228
 - relapse 10
 - renal 153
 - signaling pathways 91
 - stem cell (CSC) 8, 148, 149, 179, 183
 - stomach 114, 115
 - therapeutics 151, 206
 - types, metastatic breast 3
 - urogenital 181
- Cancer cells 1, 2, 6, 23, 32, 33, 34, 35, 62, 70, 140, 153, 179, 182, 187, 200, 202, 204, 206, 244
 - cervical 153
 - human breast 182, 187, 204

- non-tumorigenic breast 179
- Cancer progression 8, 43, 74, 182, 197, 205
 - cells promote breast 8
 - influence breast 43
 - luminal-type breast 205
- Cancer risk 26, 198, 248
 - postmenopausal breast 26
 - reduced breast 248
- Carcinogenesis 43, 69, 71, 109, 110, 112, 114, 116, 120, 197, 204
 - cervical 114
 - gastric 114
- Carcinomas 3, 4, 8, 9, 23, 64, 91, 110, 111, 112, 114, 115, 116, 119, 120, 199, 246
 - anogenital 114
 - associated fibroblasts (CAFs) 9, 246
 - cervical squamous cell 91
 - cell progression 112
 - cervix 114
 - colorectal 120
 - cribriform 4
 - cystic 199
 - malignant 112
 - metastatic 8
 - oropharyngeal 116
 - uterine corpus endometrial 91
- Catalog of somatic mutations in cancer (COSMIC) 97
- Caveolae mediated endocytosis 176
- CDK inhibitors 202
- Cell 2, 7, 10, 42, 130, 145, 203
 - adhesion 2, 145
 - apoptosis 7
 - lymphopoiesis 42
 - lysis 130
 - mediated cytotoxicity 10
 - programmed death 203
 - transcription 145
- Cell cycle 69, 71, 74, 156, 179, 196, 202, 205, 206, 249
 - arrest 69, 74, 156, 179, 202, 249
 - pathway 206
 - progression 71, 202, 206
 - regulation 196, 205, 206
- Cell death 69, 71
 - machinery 71
 - pathways 69
- Cell growth 91, 116, 153, 201, 206, 251
 - control cancer 91
 - factors survival signals 251
 - pathways 116
- Cell proliferation 5, 7, 14, 25, 41, 113, 145, 148, 150, 151, 202, 203, 204, 205
 - leukocyte 113
- Cell signaling 112, 145, 201
 - deregulate 112
 - hormone-mediated 145
- Cellular 7, 112, 143, 181
 - metabolism 112, 181
 - pathways 7, 143
 - transformation 112
- Chemoprevention 197
- Chemo-radiotherapy 71, 247
- Chemotherapeutic agents 155
- Chemotherapy 74, 119, 120, 144, 155, 156, 219, 225, 226, 242, 243, 246, 247, 248, 249
 - conventional 74, 156
 - drugs 246
- Chromatin 141, 142, 146, 147
 - condensation 142
 - conformation 142, 147
- Clathrin 174, 175, 176, 177, 181
 - caveolae independent endocytosis (CCIE) 176
 - caveolin-independent endocytosis 175
 - mediated endocytosis (CME) 174, 175, 177, 181
- CMF therapy 246
- CNS diseases 117
- Colony-stimulating factor 11
- Combination 73, 155, 156, 246
 - chemotherapy 246
 - of PAPRI and inhibitor of cyclin-dependent kinase 73
 - therapy 155, 156, 246
- Combined epigenetic therapies 140
- Computational methods 92
- Computers, fast-processing 228
- Computer tomography 228

Subject Index

Concentration, metallic 202
Cone beam computed tomography (CBCT)
235
Copy number analysis 94
Correlation analysis 98, 99
Cowden syndrome 68
Cutaneous T cell lymphoma (CTCL) 154, 155
Cyclin-dependent kinases 73, 75, 202
Cyclooxygenase 205
Cysteine oxidation 112
Cytidine deaminase 154
Cytokine(s) 22, 34, 35, 36, 37, 40
and steroids synthesis 37
anti-inflammatory 22, 36
in breast cancer 35
immunosuppressive 34
inflammatory 37, 40
signaling 22
Cytochrome 112, 118
releasing mitochondrial 118

D

Damage, oxidative 110
Dampened immunogenicity 34
DDR 69, 71, 72
dysfunctional 69
pathways 71
response associated factors 71
targeting therapies target pathways 72
DDR-associated genes 71, 72, 75
pathway inhibitors 75
pathways 71
proteins 72
repair enzymes 72
Defects 10, 34, 62, 69, 71, 142, 143, 144, 151
transcriptional 142, 143
Defects in DNA 62, 68
damage response 62
repair component pathway 68
Defense system 115, 201
disturbed antioxidant 115
Dehydroepian drosterone sulfate 39

Breast Cancer: Current Trends in Molecular Research 263

Delivery 119, 171, 178, 182, 184, 185, 186,
187, 226, 229, 231, 233
cytosolic 178
mediated therapeutic 182
systems, nano-therapeutic 184
targeted NPs 182
targeted therapeutic 182
techniques 226
tumor-targeted 182
Dendritic cells (DCs) 12, 32, 33, 37, 40, 41,
173
Discovery 2, 7, 92, 130, 132, 133, 196, 221
anticancer drug 7
Disease(s) 2, 25, 31, 37, 62, 63, 67, 68, 66,
129, 130, 131, 132, 135, 143, 144, 149,
172, 197, 204, 225, 226, 232, 236, 249,
251
aggressive 144
autophagy-associated 204
cardiovascular 197
free survival 25, 31, 37, 66, 226
malignant 37
microscopic 232
obesity-associated 197
progression 2, 129, 149, 249
systemic 225
Disorders 197, 204
inflammatory 197
neurodegenerative 197
neurological 204
DNA 68, 70, 72, 74, 95, 115, 140, 141, 142,
143, 146, 147, 181, 200
alkylating agents 70
alkylation lesions 70
amplification 95
charged 147
deaminate 115
demethylases 141
genomic 143
hypermethylation 142
hypomethylation 142, 146
lesions 68, 72
methylate 141
methylation in cancer cells 142
methyltransferases 140, 141

- microarray technology 200
 - replication 74
 - synthesis 181
 - DNA binding 142
 - affinity of DNA-binding proteins 142
 - DNA damage 62, 69, 71, 74, 116, 202, 221, 231, 249
 - oxidative 202
 - repair pathways 69
 - DNA methylation 89, 91, 96, 97, 139, 140, 141, 142, 145, 147, 153, 155
 - and histone modifications 142, 153
 - DNA repair 62, 67, 68, 69, 72, 112, 145, 147, 249
 - component pathway 68
 - genes 72
 - mechanisms 69
 - system 112
 - DNA repair pathways 62, 69, 71
 - in event of DNA damage 71
 - license cancer cells 71
 - DNMT inhibitors (DNMTi) 153, 154, 155
 - Double-strand breaks (DSBs) 68, 71, 72, 73, 220
 - Downregulating E-cadherin expression 6
 - Downstream targets 7
 - Drugs 3, 69, 185, 186, 187, 196, 200, 246, 249, 251
 - chemotherapeutic 69, 200
 - novel immunotherapy 249
 - Ductal hyperplasia (DH) 1, 145, 146
- E**
- Effector 12, 31
 - anti-proliferative 31
 - Effects 37, 40, 74, 109, 111, 112, 118, 119, 120, 182, 197, 198, 206, 226
 - anticancer 206
 - antitumor 74, 120, 182
 - chemopreventive 198
 - cytostatic 112, 118, 119
 - genotoxic 111
 - immuno-suppressive 40
 - mutagenic 197
 - of adjunct radiotherapy 226
 - pro-tumorigenic 37
 - tumor-promoting 109
 - Efficacy 73, 74, 119, 120, 143, 154, 155, 171, 172, 197, 201, 244
 - therapeutic 73, 155, 171, 172
 - transcriptional 143
 - EGFR 74, 148
 - promote breast invasion 148
 - signaling 74
 - Electronic portal imaging devices (EPIDs) 235
 - Electrophoresis 132
 - Elicit tumor cell cytotoxicity 118
 - Endocytic pathways 171, 173, 176, 177
 - Endocytosis 171, 172, 173, 174, 176, 177, 178, 180
 - caveolae-mediated 176, 177
 - clathrin-mediated 174, 177
 - energy-dependent 177
 - mechanisms 172
 - Environment 11, 176, 184, 202, 227, 236
 - hydrolytic 176, 184
 - hypoxic 11
 - immune 236
 - pro-inflammatory 202
 - Enzymes 23, 38, 75, 109, 111, 117, 141, 148, 181, 197, 201
 - antioxidant 201
 - aromatase 38
 - elevated telomerase 23
 - ribonucleotide reductase 181
 - Epidermal growth factor receptor (EGFR) 3, 9, 89, 130, 175, 177, 178, 179, 185, 248
 - Epigenetic 140, 143
 - imbalance in cancer 143
 - programming 140
 - Epithelial cells 8, 23, 24, 35, 41, 64, 70, 114, 115, 176
 - gastric 114, 115
 - Epithelial-mesenchymal 1, 2, 6, 7, 24, 36, 118, 119, 145, 148, 151, 197
 - interactions 24

Subject Index

transition (EMT) 1, 2, 6, 7, 36, 118, 119,
145, 148, 151, 197
ER-induced 22, 30, 149
cell proliferation and normal development
22, 30
repression 149
ER-positive breast 22, 25, 31, 153, 247
cancers 22, 25, 31, 247
tumor tissue 153
Erythropoiesis 30
Esophageal cancer leukemia 92
Estrogen-induced breast tissue proliferation 26

F

FAC chemotherapy 246
Factors 7, 8, 9, 34, 35, 36, 38, 43, 62, 64, 87,
89, 113, 114, 118, 225, 235, 242, 243
angiogenesis-inducing 7
angiogenic 35, 36
etiologic 114
genetic 243
proangiogenic 113
tumor cells start secreting
immunosuppressive 34
tumor-derived 9
Fanconi anemia (FA) 69, 180
Fibroblast cells 9
Fibroblasts 8, 9, 24, 173, 176
carcinomas-associated 9
interstitial 9
tumor-associated 8
Folic acid 180, 186
targeting ligand 180
Formyl peptide receptors (FPRs) 180
Fragile sites miRNAs deregulation 143
Function 6, 8, 10, 11, 34, 40, 41, 111, 115,
117, 140, 141, 142, 150, 180, 183, 233
diverse biological 40
invasion-suppressor 6
macrophage 11, 40
non-coding RNA 150
non-angiogenic 8
pleiotropic 111

Breast Cancer: Current Trends in Molecular Research 265

thymic 41
Functional genomics 95

G

Gastric 114, 115
cancer 115
carcinogenesis propensity 114
carcinoma 114, 115
Gastritis 115
Gemcitabine 156
Gene(s) 2, 7, 11, 12, 36, 38, 67, 68, 87, 90, 91,
92, 93, 94, 98, 99, 111, 141, 143, 145,
146, 147, 152, 197, 200
aromatase 38
encoding isoforms, distinct 111
human cancer driver 98
metastatic 36
methylated 152
miRNAs encoding 143
mutant 2, 68
reactivation 146
regulating 197
transcription 7, 141, 143, 147
tumor expression 92
Gene expression 87, 88, 89, 93, 95, 97, 140,
142, 144, 146, 199, 202
omnibus (GEO) 88, 95
Gene expression profiling 64, 66
microarray-based 66
Gene silencing 141, 150
hypoxia-mediated 150
Genetic driver mutations 143
Genome 92, 145, 146, 201
mammalian 145
Genomic 62, 68, 69, 71, 73, 74, 86, 88, 95,
142, 154
imprinting 140
instability 62, 68, 69, 71, 74, 142, 154
integrity 69, 73
Germline mutation 62, 68, 69, 71
in breast cancer susceptibility genes 62
Germline pathogenic mutations 89
Glioblastoma 155

- Glutathione peroxidase 201
Glycohydrolase 73
G-protein-coupled receptor (GPCR) 180
Grenzray therapy 222
Growth hormones 176
Gynecologic cancers 91, 100
- H**
- Head and neck 115, 154
 cancers 115, 154
 Carcinoma 115
Hematopoiesis 36
Her2 protein 5
Hereditary non-polyposis colorectal cancer (HNPCC) 69
High-throughput 86, 95, 132
 assay 132
 sequencing 86, 95
Histone 139, 141, 148
 acetyl transferases (HATs) 141, 148
 deacetylases 139, 141
 demethylases 141, 148
 methyltransferases 141, 148, 149, 153
Hormonal replacement therapy (HRT) 31, 32
Hormone 3, 8, 24, 25, 26, 38, 43, 66, 88, 94, 117, 118, 149, 225, 230, 236, 243, 247
 postmenopausal 26
 sex 26, 38, 43
 steroid 24, 25, 38, 40, 118
 regulated tumorigenesis 149
Hormone therapy 26, 64, 144, 219, 225, 226, 236, 243, 247, 248, 250
 adjuvant 243
 menopausal 64
 neo-adjuvant 248
 treatment 247
Human 40, 114, 116
 NK cells 40
 papillomavirus 114, 116
Humoral immune response 129
Hyaluronic glucosaminidase 152
Hyperplasia 1, 39, 145
 breast ductal 145
- Hypotension 119
- I**
- Immune cells 2, 8, 9, 10, 32, 33, 35, 39, 88
 tumor-promoting 35
 tumor-suppressing 35
Immune 9, 249
 cells and breast cancer progression 9
 checkpoint pathways 249
Immune responses 12, 32, 33, 34, 35, 38, 39, 180, 249, 251
 inflammatory 35
Immune system 12, 32, 33, 35, 38, 41, 42
 response 12
Immunity 10, 12, 13, 34, 111, 197
 anti-tumor 12, 13
 macrophage-mediated 111
 mammalian 10
Immunoaffinity chromatography 132, 133
Immuno-inductive effects 22
Immunosuppressive 34
 cells 34
 factors 34
Immunotherapy 2, 33, 93, 119, 120, 235, 242, 243, 248, 249, 251
 response 251
Infiltrating ductal carcinoma 3, 65
Infiltration, immune 91
Inflammation 23, 39, 115, 197, 199, 204, 251
 carcinoma 199
Inhibiting DNA synthesis 112
Inhibitors 2, 62, 72, 73, 113, 151, 153, 155, 156, 203, 248
 epigenetic 153, 155, 156
 histone deacetylase 73
 immune checkpoint 2
 of apoptosis protein 203
 tyrosine kinase 248
Intensity-modulated 219, 226, 230, 232, 233
 radiation therapy (IMRT) 219, 226, 230, 232, 233
 radiotherapy 232
Invasion 11, 145

Subject Index

tissue 145
tumor cell 11
Invasive) 4, 65, 87, 88, 152, 199
 ductal carcinoma (IDC) 4, 65, 88, 152, 199
 lobular carcinoma (ILC) 4, 87, 88, 199
Ionizing radiation 73, 201, 219, 220, 221, 231,
 244
Irradiation 228, 229
 accelerated partial breast 229

K

Kinases 6, 75
 threonine 6
 tyrosine 75
KRAS signaling 93
Kupffer cells 118

L

Lesions 112, 116
 dysplastic 116
 neoplastic 112
LINAC-based radiotherapy 223
Lipid 30, 115, 201, 202
 metabolism 30
 peroxidation 115, 201, 202
Lipoprotein lipase 200
Liposomes 183, 187
 targeted 183
Lipoxygenase 205
Low-density lipoprotein (LDL) 40, 174, 175
Luminal-type guanine nucleotide-exchange
 205
Lumpectomy 244
Lung 4, 40, 116, 153, 180, 227, 228, 229, 230,
 232, 233
 carcinogenesis 116
 carcinoma 116
Lymph node metastasis 71, 117, 148
Lymphocytes 12, 13, 33, 36, 39, 40, 42, 88, 90
 adaptive immune 33
 immature 42
 tumor-infiltrating 88, 90

Breast Cancer: Current Trends in Molecular Research 267

Lymphoid recovery 39
Lynch syndrome 69
Lysosome 174, 176, 184

M

Macrophage(s) 8, 9, 10, 11, 13, 32, 33, 35, 36,
 37, 38, 39, 40, 42, 43, 174, 185
 activating factor (MAF) 32
 migration inhibitory factor 11
 murine 174, 185
 tumor-associated 9, 11, 35
Macropinocytosis 173, 175, 177
Macropinosomes 177
Malignancies 1, 2, 12, 37, 63, 69, 70, 113,
 143, 153, 181
 hematological 69, 70
 myeloid 153
Malignant transformation 7, 181
Mammary duct morphogenesis 8
Mammography 63, 152
Management, cancer disease 219
Mass spectrometry 132, 133
Matrix metalloproteinases 6, 9, 36, 113
Mechanisms 143, 145
 antioxidant 197
 epigenetic 143, 145
 host defense 173, 184
 miRNA maturation 151
 prooxidant 202
Medullary carcinoma 199
Mesenchymal stromal/stem cells (MSC) 8
Metabolites 8, 113, 116, 119, 129
 hazardous 119
Metalloproteinase 113
Metaplasia, intestinal 114
Metaplastic carcinoma 199
Metastasis 1, 2, 6, 7, 8, 10, 11, 12, 32, 93, 94,
 115, 118, 148, 149, 150, 151, 205, 226,
 235
 asymptomatic 235
 bone 226
 cancer cell 93
 progression 8

- gastric cancer lymph node 115
 - resist tumor 32
 - Metastatic 1, 3, 4, 12, 63, 88, 94, 97, 98, 119, 139, 140, 144, 155, 247
 - breast cancer 1, 3, 4, 88, 94, 140, 247
 - cancer 94
 - cascade 119
 - disease 63, 97, 139, 144, 155
 - tissues 98
 - tumors 12, 119
 - Methods 89, 90, 93
 - bioinformatics analysis 93
 - clustering 89
 - data-based subtyping 89
 - machine learning 90
 - Methylation 97, 146
 - analysis of repetitive DNA elements 146
 - in human cancer 97
 - Methyltransferases 94, 139, 149
 - histone lysine 94
 - Microenvironment 11, 37, 93, 112, 114, 116
 - cervical 114
 - immune 93
 - neoplastic 112
 - MicroRNA Sequence 100
 - Migration 8, 23, 35, 148, 151, 179, 183
 - epithelial-cell 35
 - MiRNAs 143, 150, 151
 - deregulated 143
 - expressed 151
 - oncogenic 151
 - Misdiagnosis 139, 152
 - Mitogen-activated protein kinase (MAPK) 250
 - Monotherapy 2, 62, 73, 75, 249
 - MTT colorimetric assay 28, 29
 - Multi-omics data analysis 90
 - Multiple genes 91
 - Mutagenesis 23, 114
 - oxide-mediated 114
 - Myelodysplastic syndrome 154
 - Myeloid-derived suppressor cells (MDSCs) 9, 10
 - Myelosuppression 70
- ## N
- National comprehensive cancer network (NCCN) 66
 - Natural killer cells (NKC) 40, 118, 173
 - Neck Carcinoma 115
 - Neo-adjuvant therapy and adjuvant therapy 243
 - Neoplasia 13, 114, 117
 - cervical intraepithelial 114
 - Neuroendocrine carcinoma 199
 - Neurotoxicity 117
 - Neurotransmission 111, 117
 - Next-generation sequencing 86, 94
 - NF-kappaB Mitogen-activated protein kinase 250
 - NHEJ repair pathway 73
 - Nicotinamide 72
 - Nitric 11, 113, 114, 118, 119
 - producing 11
 - Nitric oxide 110, 114, 115, 116, 117, 118, 119
 - and lung carcinoma 116
 - donors 118, 119
 - gas 110
 - generation 118
 - in brain tumor 117
 - in gastric carcinoma 114
 - pathway 118
 - release 114
 - signaling 115
 - Nitric oxide synthase 109, 110, 111, 116, 117
 - endothelial 110
 - Non-cancerous growth 68
 - Non- DNA repair pathways 72
 - Non-Hodgkin's lymphoma 36
 - Non-homologous end-joining (NHEJ) 69, 73
 - Normal tissue complication probability (NTCP) 221
 - NOS-encoding cDNA sequences 119
 - NPs 173, 175, 180, 181, 184, 186, 188
 - delivery system 188
 - drug delivery systems 181
 - endocytosis 175
 - lipid 180, 186

Subject Index

liquid-crystalline 186
phagocytosis 173
protein binding 184
Nuclear pleomorphism 65
Nucleolin overexpression 182
Nucleoplasm 182
Nucleotide excision repair (NER) 69, 249

O

Omics landscape 100
Oncogenes 2, 115, 140, 142, 143, 149, 150
 putative 149
Oncogenic 90, 143, 201
 driver genes 90
 transformation 143, 201
Oncomine mining 92
Oral squamous cell carcinoma (OSCC) 115, 118
Ovarian 32, 72, 75, 91, 92
 cancer 32, 72, 75, 92
 cystadenocarcinoma 91
Oxidative stress 39, 68, 110, 111, 201
Oxide-mediated cytotoxicity 118
Oxidized low-density lipoprotein 40

P

Pan-cancer analysis 86
PAPR inhibitors 75
Pathways 2, 10, 87, 91, 94, 143, 178, 184, 197
 dysregulate apoptotic 2
 endo-lysosomal 178
 genetic 87
 metabolic 197
 miRNA biogenesis 143
 mTOR 94
 mutated 94
 oncogenic 91
 phagocytic 184
 pro-tumorigenic 10
Pathways Inhibition 249, 250, 251
 for cancer therapy 249
Pattern recognition receptors (PRR) 180

Breast Cancer: Current Trends in Molecular Research 269

Peptides 178, 180, 183, 184, 186, 188
 amino acid 178, 183
 fibronectinmimetic 183
Peutz-Jeghers syndrome 68
Phagocytic 33, 180
 cells 33
 leucocytes 180
Phagocytosis 173, 174, 175, 184
Phagosomes 173
Phenotypes 2, 7, 96, 118, 182, 183
 mesenchymal 2, 7, 118
Phosphatases 41, 90, 202
 protein tyrosine 90
Phosphate dehydrogenase 200
Phosphorylation 41, 111, 140, 147, 178
 kinase-mediated 111
Pinocytosis 173, 174, 177
 clathrin-dependent 177
Plasmacytoid 33
Pleiotropic cytokine 35, 36, 41
Poly-ADP-ribose polymerase (PARP) 72, 249
Polymerase 71
Polyphenol-enriched blueberry preparation (PEBP) 205
Postmenopausal women 22, 24, 26, 27, 42, 247, 248
Processes 2, 7, 22, 23, 32, 33, 34, 37, 39, 72, 88, 114, 118, 142, 173, 174, 181, 227
 cancer immunoediting 37
 carcinoma 118
 clathrin-mediated endocytosis 181
 gene silencing 142
 lysosomal mediated degradation 181
 neoplastic 114
 oncogenic 88
Production 11, 34, 35, 40, 41, 42, 110, 112, 115, 117, 201, 223
 ceramide 112
 metalloproteinase 11
 pro-inflammatory cytokines 40
Progesterone 3, 5, 24, 27, 65, 66, 91, 110, 117, 118, 130, 177, 200, 201, 242, 243
 receptor (PR) 3, 5, 27, 65, 66, 91, 110, 130, 177, 200, 201, 242, 243

- Prognosis 6, 25, 31, 130, 133, 134, 139, 144, 152, 153, 156, 196, 200
- Prognostic factor 31, 225, 236
- Progression of tumorigenesis 69
- Properties 119, 196, 202
antioxidant 196, 202
- Prostate 153
- Proteases 9, 35, 118
activating caspase family 118
- Protective connective tissues 23
- Protein(s) 6, 7, 37, 67, 68, 111, 112, 113, 116, 118, 129, 130, 132, 133, 144, 147, 176, 180, 184, 185, 196, 197, 202, 203, 206
adsorption 184, 185
anchored cell-membrane 180
apoptosis-linked 112
apoptosis-related 118
bone morphogenetic 37
degradation 6, 203
microarray 132, 133
oxidation 202
sensor 69
vesicle-associated membrane 176
- Proteolysis 131
- R**
- Radiation 219, 228, 243, 244, 245, 247
oncologist 228
therapy 219, 243, 244, 245, 247
- Radical mastectomy 244
- Radiotherapy 155, 156, 219, 220, 225, 226, 227, 228, 229, 231, 232, 242, 243, 244, 245, 246, 250
combination 244
dynamic intensity-modulated 232
postmastectomy 229
treatment 245
therapy 219
tumor cells resistance 250
- Reactive 68, 69, 109, 110, 111, 112, 115, 116, 196, 201, 202
nitrogen species (RNS) 109, 110, 111, 112
oxygen species (ROS) 68, 69, 110, 115, 116, 196, 201, 202
- Regulating Autophagy 203
- Regulation 34, 36, 41, 43, 94, 111, 119, 143, 145, 150, 151, 198, 206, 249, 250
cytokine 43
epigenetic 94, 143
epigenetic post-transcriptional 150
transcriptional 34
- Regulator protein residues 112
- Relapse 7, 63, 87, 152, 182, 200, 201
free survival (RFS) 7, 200, 201
metastatic 87
- Release proteases 6
- Repair responses 69
- Repetitive DNA elements 146
- Replication 72, 74
machinery 72, 74
protein 74
stress 74
- Rheumatoid arthritis 36, 42
- Risk, carcinoma 115
- RNAs 129, 150
and regulatory molecules 150
- Role 9, 24, 33, 40, 41, 112, 118, 148
immune-regulatory 41
immunosuppressive 33, 40
inhibiting 24
of nitric oxide in promoting carcinogenesis 112
oncogenic 148
suppressive 41
tumoricidal 118
tumor-promoting 9
- S**
- Sentinel lymph node (SLN) 244
- Signaling 9, 62
dysregulated hormonal 62
paracrine 9
- Single 69, 88, 176, 197, 248, 250
cell RNA sequencing 88
strand break repair (SSBR) 69

Subject Index

transduction 176, 197, 248, 250
SMAD 7
 dependent signaling pathway 7
 signaling pathway 7
Somatic copy number alterations (SCNA) 91, 94
Stress 69, 110, 111, 201
 chemical 111
 genotoxic 69
 nitrosative 110
Suppress cytotoxic 12
Surgery 87, 93, 155, 219, 225, 226, 229, 242, 243, 244, 245, 247
 breast-conserving 87, 226, 229, 243
 breast-sparing 225
Symptoms 70, 220, 226, 236
 lymph-toxic 70
Synthesis 111, 116, 118
 suppressed 118
System 13, 72, 184
 deficient DNA repair 72
 phagocytic 184
 proteasomal 13
 reticuloendothelial 184

T

Techniques 90, 228
 breath-holding 228
 machine learning 90
Testosterone 25, 26, 27, 29, 30, 39, 40, 41, 42
 aromatase enzyme metabolizes 30
Therapeutic anti-cancer vaccines 33
Therapy 2, 35, 41, 88, 144, 151, 152, 153, 156, 222, 225, 226, 242, 243, 244, 249, 251
 androgen deprivation 41
 endocrine 2, 88, 152, 243
 epigenetic 144, 153, 156
 immune 35
 molecular mechanism-based 2
 systemic 225, 242
Tissues 25, 41, 111, 114, 116
 androgen-responsive 25

Breast Cancer: Current Trends in Molecular Research 271

colon cancer 114
lung cancer 116
malignant 41
neuronal 111
Tolerance 12, 34, 233
 immune 12, 34
 immunological 34
Transcription factors (TFs) 6, 7, 12, 112, 140, 142, 146, 175, 205
Transferrin 174, 175, 181, 182, 186
 iron-binding 181
 receptor (TfR) 175, 181, 182, 186
Transition, mesenchymal 2, 6, 36
Transmembrane glycoprotein 179
Transport, transendothelial 176
Transposons 143, 145
Transvaginal ultrasonography 236
Treatment planning systems (TPS) 226, 227, 228, 230, 234, 235
Tumors 7, 8, 9, 11, 12, 32, 35, 37, 42, 69, 87, 89, 98, 111, 117, 143, 147, 151, 197, 202, 205, 220, 221, 229, 230, 233, 244, 251
 angiogenesis 147
 breast tissue 151
 control probability (TCP) 221
 growing 7, 12
 immunity 32
 influence 89
 initiating cells (TICs) 8, 143
 low-angiogenic 7
 necrosis factor (TNF) 35, 37, 42, 111, 251
 parenchyma 9
 progression regulation 205
Tumor-associated 9, 11, 13, 33, 35, 129, 131, 132, 133, 134, 135
 antigens (TAAs) 33, 129, 131, 132, 133, 134, 135
 macrophages (TAMs) 9, 11, 35
 stroma 13
Tumor cell 9, 117, 204
 death 204
 homeostasis 117
 proliferation 9

Tumor growth 7, 11, 12, 24, 32, 33, 35, 38,
43, 112, 113, 119, 179, 182, 204
 arrest 119
 inhibition 182
 maturation support 33
 reducing 179
 stimulate 12
Tumorigenesis 14, 32, 69, 116, 142, 143, 145,
146, 148, 182
Tumorigenicity 7, 148, 149, 150
Tumor suppressor 7, 115, 140, 142, 143, 149,
150, 203
 genes (TSGs) 115, 140, 142, 143, 149, 203

U

Uterine 91
 carcinosarcoma 91
 corpus endometrial carcinoma (UCEC) 91

V

Vascular endothelial growth factor (VEGF) 7,
8, 11, 34, 36, 113, 115, 117
VEGF expression 11, 12
VEGF signaling 8

W

Werner helicase syndrome 69
Western blotting 132
Whole 87
 exome DNA sequencing 87
 genome sequencing 87